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6ABSTRACT
Male sex hormones (androgens) are important for the normal development of the male 
sexual characteristics and maintenance of the male reproductive system, including the 
prostate gland. Androgens are also involved in pathological conditions such as prostate 
cancer, which is the third leading cause of cancer-related deaths for men in western 
industrialized countries. Androgens mediate their action through the androgen receptor 
(AR), a ligand-dependent transcription factor of the nuclear receptor superfamily. Upon 
ligand-binding, AR translocates to the nucleus and binds specific sequences in the 
promoter or enhancer of androgen-responsive genes. Androgen-regulated genes have thus 
been of special interest for a long time for better understanding of normal prostate 
biology and in the search for potential biomarkers and therapeutic targets in prostate 
cancer. One such gene that was recently discovered is kallikrein 4 (KLK4), which is 
androgen regulated and specific to the prostate for expression. KLK4 belongs to the 
human tissue kallikrein family, consisting of 15 closely related members whose genes are 
tandemly located in a large cluster on chromosome 19q13.4. Interestingly, KLK4 was 
shown to have a different gene structure than the other members of this family, as KLK4 
transcripts did not contain the putative exon 1 predicted to encode a signal peptide 
targeting the protein for secretion. The lack of a signal peptide resulted in an intracellular 
KLK4 which was predominantly expressed in the nucleus of prostate cancer cells and in 
the basal cells of the prostate epithelium. KLK4 was also overexpressed in malignant 
prostate as compared to normal prostate glands, both at the mRNA and protein level. 
Furthermore, we demonstrated that overexpression of KLK4 induces proliferation of the 
prostate cancer cell lines PC-3 and DU145. The increased rate of proliferation was at 
least in part due to changes in the expression of cell cycle regulatory genes. We suggest 
that KLK4 may have a role in prostate cell growth and is an important factor in the 
development and progression of prostate cancer; thus, KLK4 has potential utility as a 
diagnostic or prognostic marker, or therapeutic target in prostate cancer therapy.
In addition to identification and characterization of androgen target genes, it is also 
important to understand the molecular details of AR function to gain full insight into 
androgen action. To that end, we studied the interactions of AR with its target sites in 
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chromatin in living cells. Using fluorescence microscopy techniques, we found that there 
is a transient and dynamic interaction of AR with target genomic sites in the presence of 
agonists, which coincides with the recruitment of chromatin remodeling complexes and 
RNA Polymerase II, resulting in transcriptional activation. The kinetics of these 
interactions are ligand-dependent, as the interaction of antagonist-bound AR was 
dramatically faster than for agonist-bound AR. Furthermore, the interaction of a 
transcriptionally compromised mutant AR with target sites was faster than for wild type 
AR, and occurred without transcriptional activation, suggesting a correlation between 
transcriptional activity and residence time on the promoter. Furthermore, there were 
intramolecular interactions between the N- and C-termini of promoter-bound AR in its 
active state which were important for transcriptional activity. Finally, we elucidated how 
AR nuclear dynamics are changed in response to altered chromatin acetylation status. 
Interestingly, and in further support of a direct correlation between nuclear dynamics and 
transcriptional activity, we found that increased AR transcriptional activity, induced by 
histone deacetylase inhibitors, resulted in reduced mobility of AR at its target promoter. 
These data challenge the traditional static view of nuclear receptor action, and support the 
more recent view of transcription factor–chromatin interactions that constitute a highly 
dynamic system in continuous flux involving transient and rapid molecular interactions. 
These findings thus provide a kinetic and mechanistic basis for regulation of gene 
expression by androgens and anti-androgens in living cells. 
8INTRODUCTION      
1. Androgens and the Androgen Receptor 
1.1. Androgens 
The male sex hormones are known as androgens, a name derived from the Greek andros,
man, and gennan, to produce. The importance of androgens was first discovered in 1849, 
when Arnold Bechter linked the behavorial and physiological changes of castration to a 
substance secreted by the testes into the bloodstream. The testicular hormone later known 
as testosterone was isolated in 1934, and artificially produced only one year later 
(Freeman et al., 2001). In the decades to follow, other androgens were also identified 
(Table 1).  
Table 1. Androgens commonly found in man 
Androgen Abbreviation Type Characteristics 
Testosterone TST Steroid hormone Produced in the testis, is the main circulating androgen 
5D-dihydrotestosterone DHT Steroid metabolite The active metabolite of TST 
Dehydroepiandrosterone DHEA Steroid hormone Produced in the adrenal cortex 
Androstenedione Andro Steroid hormone Produced in the testis, adrenal cortex, and ovaries 
Androstenediol - Steroid metabolite Is a regulator of gonadotropin secretion 
Androsterone - Steroid metabolite Chemical by-product from break-down of other androgens 
Androgens are necessary for normal development of the penis, scrotum, testicles, and 
male secondary characteristics at puberty. Testosterone is the main circulating androgen, 
and in the developing male, the fetal testis secretes testosterone at sufficient levels to 
stimulate the differentiation and growth of the male reproductive organs. After birth, the 
serum testosterone levels decrease to a low level maintained until puberty, when the level 
increases to the adult range (Isaacs, 1994).  
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Approximately 90% of the androgens are produced by the Leydig cells in the testes, 
while the remainder is secreted by the adrenal cortex. The production of testosterone is 
regulated by negative feedback regulation by LH (Lutenizing Hormone) and the LHRH 
(Lutenizing Hormone Releasing Hormone) via the gonad-hypothalamus-pituitary axis 
(see Figure 1). The action of androgens can be blocked by anti-androgens which are 
described in more detail below. In the blood, testosterone is found complexed to either 
albumin (54%) in a low affinity fashion, or to SHBG (Steroid Hormone Binding 
Globulin) (44%), while only 1-2% is free. Testosterone can either enter the cell passively 
in its free form or by dissociation of albumin near the membrane, or it can be actively 
transported into the cell through a membrane receptor when bound to SHBG (Rosner et 
al., 1999) (see Figure 3). Once inside the cell, 90% of the testosterone is irreversibly 
converted to its more active metabolite DHT (5D-dihydrotestosterone) by the enzyme 5D-
reductase in a sequential series of steps involving the cofactor NADPH (Levy et al., 
1990). Testosterone or DHT then binds to the AR (Androgen Receptor), where DHT has 
five-fold higher affinity.  
1.2. Androgen Receptor   
The effects of androgens are mediated by AR, which is a ligand-dependent transcription 
factor that belongs to the nuclear receptor (NR) superfamily. This family of transcription 
factors consists of more than 150 members that are likely to have arisen from a single 
ancestor gene (Escriva et al., 2000) and comprise the largest family of transcription 
factors known. The importance of this protein family can be explained by the diversity 
and importance of their ligands: from sex steroids and thyroid hormones, to bile acids and 
vitamins (Mangelsdorf et al., 1995). Historically, these ligands were isolated in the early 
part of the 20th century based on their abilities to affect development, differentiation, 
metamorphosis, and homeostatis. Many of these ligands are also associated with human 
diseases, such as many cancers (see e.g. (Wiseman & Duffy, 2001; Singh & Kumar, 
2005)). In the mid-1970s, it became evident that steroid hormones were targeted to their 
responsive tissues by the presence of specific high affinity receptor proteins. Due to the 
lipophilic character of the steroid hormones, they can pass through the lipid bilayer of the 
cell membrane and interact with intracellular receptors. The identification of hormone 
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responsive genes within these tissues then led to the identification and cloning of the 
steroid hormone receptors in the mid-1980s. Later studies revealed the presence of 
receptors for all known nuclear hormones, as well as a myriad of orphan receptors, which 
led to the concept of a nuclear receptor superfamily (reviewed in (Robinson-Rechavi et 
al., 2003)).  
Figure 1. The role of androgens in the gonad-hypothalamus-pituitary axis
GnRH (Gonadotropin Releasing Hormone)/LHRH (Lutenizing-Hormone Releasing Hormone) is 
produced in the hypothalamus which signals the pituitary gland to produce LH (Lutenizing 
Hormone). LH then stimulates the Leydig cells of the testes to produce testosterone (TST), which 
is released into the bloodstream. In the prostate, TST is converted to DHT (5D-
dihydrotestosterone) which activates the androgen receptor. TST and DHT production is 
regulated via a negative feedback loop to the hypothalamus. Anti-androgens can block the 
function of TST in the prostate and adrenal androgens produced by the adrenal cortex. 
Orchiectomy is medical castration for the inhibition of testosterone production. 
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NR family members can be classified into three groups based on their ligand binding 
properties: steroid hormone receptors, RXR (Retinoid X Receptor) receptors, and orphan 
receptors (sometimes also divided in dimeric and monomeric orphan receptors). AR 
belongs to the steroid hormone receptor subfamily, which also includes the progesterone 
receptor (PR), glucocorticoid receptor (GR), estrogen receptor (ER), and 
mineralocorticoid receptor (MR). The steroid hormone receptor subfamily is activated 
upon binding of its steroid ligand that are small lipophilic molecules, and in general bind 
inverted half-sites in DNA as homodimers, although other binding sites are also reported 
(for a review, see (Beato & Klug, 2000)). The RXR receptors bind DNA (both direct and 
inverted half sites) as heterodimers, usually with RXR as partner. The orphan receptors 
form the largest group of NRs, for which no ligands were originally identified, and these 
receptors bind DNA either as homodimers, or as monomers, to direct repeat of single 
half-sites (Mangelsdorf et al., 1995; Khorasanizadeh & Rastinejad, 2001).  
1.2.1. AR gene and protein structure 
The AR gene is localized on chromosome Xq11.2-12. It consists of eight exons, which 
encodes a 98 kDa protein (110 kDa on SDS-PAGE) (see Figure 2). Only one AR cDNA 
has been identified, so the various AR ligands probably bind the same receptor (Lubahn 
et al., 1988a; Lubahn et al., 1988b). The NRs have a common protein structure, with 
three distinct domains: a divergent N-terminal domain (NTD), a highly conserved DNA 
binding domain (DBD), and a moderately conserved C-terminal ligand binding domain 
(LBD). In AR, the NTD contains one large activation function (AF1) which is made up 
of two discrete regions: one required for full ligand-inducible transcriptional activity 
(Transcription Activation Unit 1, TAU-1) and one ligand-independent region (TAU-5) 
(Jenster et al., 1991; Simental et al., 1991; Jenster et al., 1995). Furthermore, the NTD 
contains two motifs involved in intramolecular interactions with the LBD (He et al., 
2000). The LBD is made up of 12 conserved D-helical regions and two anti-parallell beta-
sheets folded into a three-layered helical sandwich (Matias et al., 2000; Sack et al., 2001; 
Pereira de Jesus-Tran et al., 2006). In addition to being involved in ligand binding, the 
LBD also stabilizes homodimerization and orchestrates interaction with coregulators. The 
other activation function, AF-2, is also placed in the LBD. It is a ligand-dependent 
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transactivation function, and is also involved in interactions with co-regulators (Jenster et 
al., 1991; Slagsvold et al., 2000). Furthermore, the AF2 core is involved in the 
intramolecular interaction with two motifs of the NTD (described in more detail in 
paragraph 1.2.4) (Doesburg et al., 1997; Langley et al., 1998; He et al., 2000). The DBD 
is made up of approximately 70 amino acids, which folds into two zinc-finger motifs in 
which two perpendicular oriented D–helices specify DNA recognition (Freedman & 
Luisi, 1993). At the border of the DBD and the hinge region, connecting the DBD with 
the LBD, there is a nuclear localization signal (NLS) that targets the AR homodimer for 
translocation to the nucleus (Jenster et al., 1993; Zhou et al., 1994). 
Figure 2. Schematic presentation of the gene, mRNA, and protein structure of AR 
(A) Chromosomal location of the AR gene. (B) Exon structure of AR mRNA, with localization of 
the polymorphic CAG and GGN repeats, with indication of which exons encode the different 
domains of the AR protein. (C) Domain-structure of the AR protein: The N-terminal domain with 
the transactivation function AF1, divided into the two discrete regions TAU-1 and TAU-5, and 
the position of two motifs involved in intramolecular N/C interaction; the central DBD with two 
zinc-finger motifs specifying ARE (Androgen Response Element) recognition; the hinge region 
and the nuclear translocation signal (NLS); and the C-terminal LBD with the ligand dependent 
transactivation function AF2. The numbering for aminoacids in the AR protein is based on 20 
polyglutamine and 16 polyglycine repeats. 
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The AR gene contains 2 polymorphic trinucleotide repeat segments, CAG and GGN, 
which encode polyglutamine and polyglycine tracts, respectively, in the N-terminal 
transactivation domains of AR. Both repeats, but especially the N-terminal polyglutamine 
repeat, have been linked to several disease states (Giovannucci et al., 1997; Kantoff et al., 
1998; Krithivas et al., 1999). The polyglutamine repeat ranges from 8 to 31 repeats in 
normal individuals, with an average of 20 repeats (Hardy et al., 1996). In vitro, the length 
of the polyglutamine repeat is inveresely correlated with AR transcriptional activity 
(Chamberlain et al., 1994; Kazemi-Esfarjani et al., 1995). Longer polyglutamine repeats 
results in decreased AR activity and is associated with impaired spermatogenesis and 
infertility (Tut et al., 1997) and generally a lower risk of prostate cancer, whereas a 
shorter repeat length is associated with hyperactive AR and may increase prostate cancer 
risk (Irvine et al., 1995; Giovannucci et al., 1997). Expansion of the polyglutamine tract 
to more than 40 repeats causes the rare neuromuscular disorder spinal and bulbar 
muscular atrophy (SBMA or Kennedy’s disease) (La Spada et al., 1991).  
1.2.2. AR transcriptional activation 
In the absence of ligand, AR is found in the cytoplasm complexed with heat-shock 
proteins (HSP). Upon ligand-binding, AR dissociates from this complex, forms a 
homodimer which is phosphorylated and translocates to the nucleus where it binds to 
androgen response elements (AREs) in the enhancers or promoters of target genes. The 
AREs contain two hexanucleotide half-sites oriented as palindromes, spaced by three 
nucleotides (AGAACAnnnTGTTCT). However, other types of AREs also exist, such as 
direct repeats and elements with altered site sequence (Robins et al., 1994; Zhou et al., 
1997; Geserick et al., 2005). Once bound to its response element, AR initiates gene 
transcription by the recruitment of chromatin modifying and remodeling complexes, 
coregulators and other factors of the basal transcription apparatus (Lemon & Tjian, 2000; 
Dilworth & Chambon, 2001; Hager, 2001; Nye et al., 2002; Orphanides & Reinberg, 
2002; Shang et al., 2002; Belandia & Parker, 2003; Huang et al., 2003; Metivier et al., 
2003). A schematic presentation of AR transcriptional activation is given in Figure 3. 
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Figure 3. AR transcriptional activation  
Testosterone (TST) dissociates from albumin close to the cell surface and diffuses into the cell, or 
enters the cell through a SHBG (Steroid Hormone Binding Globulin) receptor. TST is converted 
to 5D-dihydrotestosterone (DHT) by the enzyme 5D-reductase, and binds the androgen receptor 
(AR). AR dissociates from the complex with heat shock protein (HSP) and dimerizes with 
another ligand-bound AR. The homodimer is phosphorylated and translocates to the nucleus. 
Here AR binds androgen response elements (AREs) of target genes, recruits coregulators and the 
general transcriptional machinery resulting in transcription of AR target genes generally inducing 
proliferation and differentiation.  
Coregulators strongly influence AR transcriptional activity, and a wide range of both 
coactivators and corepressors for AR have been described (for reviews, see e.g. (Heinlein 
& Chang, 2002; Wang et al., 2005a; Burd et al., 2006)). These augment or repress AR-
mediated transcription through variable mechanisms, such as modulating ligand 
selectivity and DNA-binding capacity, histone modifications, or recruitment of chromatin 
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remodelling complexes and other factors of the general transcriptional machinery. 
Coregulators can be categorized based on their functional characteristics, and can be 
divided into two major types. Type I coregulators function primarily with AR at the 
target promoter, promoting DNA occupancy, chromatin remodelling or by recruitment of 
general transcription factors associated with the RNA Polymerase II (PolII) holocomplex. 
Examples of these coregulators are CBP (CREB Binding Protein)/p300 and SRC-1 
(Steroid Receptor Coactivator-1), which both harbour histone acetyl transferase (HAT) 
activity, and also the SWI/SNF chromatin remodelling complex. The type II coregulators 
function mainly through modulating the appropriate folding of AR, aiding in ligand 
binding or facilitating AR intramolecular N/C interaction, thereby contributing to AR 
stability or influence its subcellular localization. This category include coregulators such 
as the ARA70 that stabilizes the ligand-bound receptor, and filamin that facilitates the 
nuclear translocation of AR (reviewed in (Heinlein & Chang, 2002)). Corepressor may in 
addition repress AR activity by inhibiting the recruitment of coactivators. The correct 
balance of coactivators and corepressors ensure the ligand and tissue-specific activity of 
AR, and a deregulation in the levels of these coregulators may cause inproper AR activity 
and therefore be involved in disease states such as prostate cancer (for review, see e.g. 
(Culig et al., 2004; Burd et al., 2006)). 
The timing and order of events in the recruitment process during transcriptional 
activation induced by AR has been under scrutiny for many years. By the use of time-
course based chromatin immunoprecipitation (ChIP) assays, the temporal recruitment of 
the AR and associated factors to AREs in chromatin have been described (Shang et al., 
2002; Kang et al., 2004; Wang et al., 2005b). These studies have revealed that there are 
differences in the ligand-induced loading of AR, its cofactors and PolII between 
promoters and enhancers of the same gene, and between different genes; however, there 
seems to be a functional coordination between the promoter and enhancer regions 
through shared factors in the transcription complex (Shang et al., 2002; Wang et al., 
2005b). Brown and colleagues suggest a model in which the agonist-bound AR is 
recruited to both the promoter and the enhancer, followed by the ordered recruitment of 
p160 proteins, CBP, and other factors, which results in a chromosomal loop that allows 
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PolII to track from the enhancer to the promoter and initiate transcription (Shang et al., 
2002; Wang et al., 2005b). In contrast to what have been observed for ER (Shang et al., 
2000; Metivier et al., 2003), there does not seem to be cyclical recruitment of AR and its 
cofactors to the promoter or enhancer (Wang et al., 2005b). Furthermore, antagonist-
bound AR was shown to be recruited to the promoter of the PSA gene, but not the 
enhancer, followed by the formation of a corepressor complex (Shang et al., 2002). 
Although the ChIP assay is a powerful tool, it has limitations in that one averages the 
events occurring in a population of cells and the process involves crosslinking which will 
obscure dynamic interactions. These limitations have recently been addressed by live cell 
imaging techniques, such as FRAP (Fluorescence Recovery After Photobleaching) and 
FLIP (Fluorescence Loss After Photobleaching), allowing the real-time imaging of 
molecules in single cells, thus making it possible to measure molecular dynamics at much 
smaller timescales compared to ChIP analysis. These techniques have been applied to the 
study of steroid hormone receptors such as AR, GR, ER and PR and suggest a much more 
dynamic interaction between the receptor and the chromatin than what was believed 
earlier (McNally et al., 2000; Stenoien et al., 2001a; Farla et al., 2004; Farla et al., 2005; 
Rayasam et al., 2005). Nuclear receptor dynamics are described in more detail in 
paragraph 2.5. 
1.2.3. AR antagonists 
Given the important role of androgens in prostate cancer development, AR antagonists or 
anti-androgens have been developed, some of which are currently used in the treatment of 
prostate cancer (see Table 3). Anti-androgens antagonize AR function by binding to the 
LBD of AR in competition with the natural agonists TST and DHT (Denis & Griffiths, 
2000; Klotz, 2000; Masiello et al., 2002). In general, the AR-antagonist complex does not 
activate transcription, although in some circumstances it can occur (Miyamoto et al., 
1998; Fujimoto et al., 1999), but it is not clear which steps in the AR signaling pathway 
are influenced. For example, it has long been held that the antagonists may block nuclear 
import or DNA binding, based largely on biochemical and in vitro experiments. 
However, data exists supporting the opposing view (e.g. (Kemppainen JA, 1992; 
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Masiello et al., 2002)). It has also been suggested, as for the estrogen receptor (ER) (for a 
review, see (Greschik H, 2003)), that antagonist-binding gives rise to a different 
conformation of the LBD compared with the agonists, thereby affecting the interactions 
of AR with coactivators and corepressors when bound to DNA (Poujol et al., 2000; Bohl 
CE, 2005). Furthermore, recent reports suggest that AR antagonists actually facilitate 
AR-DNA association, but inhibit transcriptional activation via the recruitment of 
corepressors to the promoter (Shang et al., 2002). In support of this view, a recent study 
demonstrated that antagonist function can be blocked by the disruption of corepressor 
recruitment (Zhu et al., 2006). However, the molecular details of AR antagonist function 
are at present still not clear. 
1.2.4. AR intramolecular N/C  interaction 
Genetic and biochemical experiments have indicated that the LBD of AR interacts with 
its NTD upon ligand binding (Langley et al., 1995; Doesburg et al., 1997; Langley et al., 
1998) similar to that observed for ER (Kraus et al., 1995). This interaction is mediated by 
two N-terminal motifs (23FQNLF27 and 433WHTLF437) and the C-terminal AF2 (He et al., 
2000; Slagsvold et al., 2000; Steketee et al., 2002; He et al., 2004), and has been shown 
to be important for optimal receptor activity, occuring only in the agonist-bound receptor 
(Doesburg et al., 1997; Schaufele et al., 2005). AR cofactors, such as the histone acetyl 
transferase CBP, facilitate this agonist-dependent N/C interaction (Ikonen et al., 1997), 
and recent studies have suggested that other AR cofactors also modulate this interaction 
(Shenk et al., 2001; Bai et al., 2005; Hsu et al., 2005). 
The initial studies on AR N/C interactions were in large part performed with truncated 
versions of the receptor in mammalian or yeast two-hybrid systems, or in biochemical 
experiments in vitro. However, agonist-dependent N/C interaction was recently also 
demonstrated for the full length receptor in human cells by the use of FRET 
(Fluorescence Resonance Energy Transfer) technology (Schaufele et al., 2005). AR with 
one fluorophore linked to the C-terminus, and another fluorophore linked to the N-
terminus was used in FRET analysis to determine the time and subcellular location of 
ligand-induced conformational changes. The AR antagonist hydroxyflutamide, OHF, 
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blocked the N/C interaction within AR, which was also closely correlated with loss of 
AR transcriptional activation. Mutation of the D-helical motif (23FQNLF27) in the NTD 
disrupted the N/C interaction, confirming the involvement of this motif in the interaction 
(Schaufele et al., 2005). Interestingly, in a recent study using the Xenopus oocytes as a 
model system, the AR N/C interaction was demonstrated to be involved in AR binding to 
chromatin, suggesting a novel role of this interaction in control of AR transcriptional 
activity (Li et al., 2006). 
1.2.5. AR modifications 
AR undergoes several posttranslational modifications such as phosphorylation, 
acetylation, ubiquitination, and sumoylation (Poukka et al., 2000; Lin et al., 2002; Fu et 
al., 2004; Faus & Haendler, 2006). For instance, the NTD of AR is constitutively 
phosphorylated at Ser-94 and becomes phosphorylated at multiple additional sites in 
response to ligand binding (Gioeli et al., 2002). The kinases responsible for the 
phosphorylation of AR and the functional importance of AR phosphorylation have, 
however, not been established, although some studies suggest MAPKs (Mitogen 
Activated Protein Kinases) and Akt to play a role (Wen et al., 2000; Gioeli et al., 2006). 
Furthermore, a cyclin-dependent kinase 1 (CDK1) has recently been identified as an AR 
Ser-81 kinase. AR phosphorylation at Ser-81 increased AR protein expression and CDK 
inhibitors decreased not only AR Ser-81 phosphorylation, but also AR protein expression 
and transcriptional activity in prostate cancer cells (Chen et al., 2006). In addition, 
tyrosine phoshorylation induced AR activity and was elevated in hormone-refractory 
prostate tumors (Guo et al., 2006). The AR acetylation sites are clustered to a KXKK 
motif in the hinge region, and mutation of the lysine residues in this motif severely 
impairs AR function and delays nuclear translocation (Fu et al., 2000; Fu et al., 2002; Fu 
et al., 2004; Thomas et al., 2004). All steroid hormone receptors are subjected to 
ubiquitination, and some of the enzymes involved have been identified, although the 
exact sites have proven difficult to map (Faus & Haendler, 2006). A similar process to 
ubiquitination is sumoylation which leads to the covalent attachment of a SUMO chain 
onto a lysine residue in the consensus \KxE motif (Seeler & Dejean, 2003). AR was the 
first steroid hormone receptor shown to be modified by SUMO, namely at K386 and 
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K520 (Poukka et al., 2000). The exact functional relevance of ubiquitination and 
sumoylation to AR function remains unclear. For an overview of post-translational 
modifications of steroid receptors, see (Faus & Haendler, 2006). 
2. Nuclear Receptor Dynamics 
Nuclear receptors mediate the action of their specific ligands through interaction with 
chromatin and the initiation of transcription of target genes. The identification of 
hormone responsive genes within different tissues and the subsequent molecular cloning 
of the steroid hormone receptors in the mid-1980s, followed by the expansion to a 
nuclear receptor superfamily, completed the initial characterization of the steroid 
hormone signaling pathway. This led to the classical model of nuclear receptor action 
where ligand-binding is followed by an allosteric change in receptor conformation which 
allows the receptor-ligand complex to translocate to the nucleus and bind high affinity 
sites in chromatin to regulate transcription (Yamamoto, 1985). The development of the 
chromatin immunoprecipitation assay (ChIP) enabled the study of NR binding to target 
promoters in cell culture models. These studies, together with more traditional 
biochemical studies on receptor-DNA interaction, built further upon the classical view of 
nuclear receptor action. According to this view, the nuclear receptors are stably 
associated with their target sites in chromatin for as long as the ligand is present, leading 
to the sequential recruitment of large transcriptional complexes (McKenna & O'Malley, 
2002; Shang et al., 2002). The assembled protein complexes were thought to have long 
residence times on the DNA template, with changes in the composition of these 
complexes occurring on the time scale of minutes or hours. However, the ChIP 
technology is not sensitive enough to detect rapid protein movements, due to the need of 
fixation of the complete DNA/protein environment of the cell which takes time. 
Furthermore, the results represent the averaging of events across a cell population and 
cannot account for heterogenous cell responses. Therefore, there has been a need to 
develop new technologies to study NR-chromatin interactions in shorter time scales. 
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2.1. Hit-and-run model for nuclear receptor action 
An alternative approach to study the dynamics of protein-chromatin interactions came 
with the advances in GFP (Green Fluorescent Protein) technology and quantitative live 
cell microscopy, allowing the visualization of protein dynamics in single living cells 
(Schaffner, 1988; Rigaud et al., 1991; McNally et al., 2000; Fletcher et al., 2002; Nagaich 
et al., 2004a; Nagaich et al., 2004b). Using this technology, a real time view of protein 
interactions with stable structures in live cells is possible. As chromosome movement is 
restrained in live cells (Marshall et al., 1997), it is possible by the use of photobleaching 
techniques, such as FRAP and FLIP, to characterize the interaction of a soluble 
transcription factor with the chromatin template. To specifically and visually study the 
interaction between NRs and their DNA response elements in chromatin, the regulatory 
sites must be amplified in the chromosome, creating a high density of binding sites, thus 
enabling the visualization of the GFP-tagged NR on its response element. This was first 
achieved with the establishment of a cell line with 200 copies of the steroid hormone 
receptor inducible MMTV (Mouse Mammary Tumor Virus) promoter stably integrated 
into the chromosome of a murine mammary adenocarcinoma cell line (McNally et al., 
2000). The LTR (Long Terminal Repeat) of MMTV contains HREs to which steroid 
hormone receptors can bind specifically (see Figure 4), and the GFP-tagged receptor 
binding to a regulatory element can thus be observed by microscopy (McNally et al., 
2000). For the use of such arrays, it is important to establish that the genes within the 
array behave similarly to normal, single copy sequences. For the MMTV array, the 
hormonal response of the MMTV promoters within the array have been rigorously 
characterized (Fragoso et al., 1998; Kramer et al., 1999). The position and extent of 
nucleosome remodeling in the amplified array was compared to that observed in low-
copy and single-copy MMTV in chromatin which showed that the chromatin 
reorganization event summed over the individual promoter copies in the array is 
indistinguishable from the event averaged over many cells with single gene copies. 
Furthermore, the kinetics of receptor induced transcription observed in the array cells is 
also identical to that originally described in low copy cells (Archer et al., 1994; Smith et 
al., 1997).  
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Figure 4. Structure and organization of the MMTV array
200 copies of a 9 kb repeat of the MMTV (Mouse Mammary Tumor Virus) promoter integrate 
into the host chromosome, creating an MMTV array. The MMTV Long Terminal Repeat (LTR) 
is characterized by a series of positioned nucleosomes (A-F) and liganded nuclear receptors (NR) 
can bind to hormone response elements (HREs) in the nucleosome B-C region, driving the 
transcription of a reporter gene (Rep). 
Direct measurements of the residence time of GR on the MMTV promoter using FRAP 
and FLIP analysis demonstrated a very rapid and dynamic interaction between GR and 
chromatin, with the receptor only present at the template for a period of 10-20 seconds at 
a time (McNally et al., 2000). These unexpected results were in disagreement with the 
traditional view of a long-term and stable transcription initiation complex. However, 
similar high mobility of other transcription related factors has been demonstrated in the 
same (Becker et al., 2002; Rayasam et al., 2005) or similar systems (Stenoien et al., 
2001a; Dundr et al., 2002; Agresti et al., 2005; Bosisio et al., 2006). This has led to the 
proposal of an alternative model for nuclear receptor action, called the hit-and-run model 
(see Figure 5). According to this model, the receptor transiently interacts with the 
promoter, recruits other factors, and is itself dynamically displaced from the promoter 
(for reviews, see e.g (Hager et al., 2004)). These confounding results and the resulting 
new model for NR action have given new insights into protein-movement in the nucleus 
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and their dynamic equilibrium with multiple targets in the nuclear compartment (Phair & 
Misteli, 2000; Misteli, 2001; Phair et al., 2004). 
The “static” versus “dynamic” view on the development of transcriptional complexes on 
regulated promoters can be integrated in a model that provides a possible resolution of 
these two apparently opposing views (Hager et al., 2006; Metivier et al., 2006). It has 
been suggested that the initiating factor, e.g. a NR, exists in the nucleoplasm in different 
complexes with its coregulators. These complexes search for their binding sites by three-
dimensional scanning of the genome, and then interact randomly and dynamically with 
response elements in target promoters (Phair et al., 2004). Most of these interactions are 
not productive, as the promoter must be in the appropriate state for the complex to initiate 
transcription. As chromatin, and also the cofactors themselves, are being modified, and 
other factors are being recruited, the stability of the complex is enhanced and may initiate 
transcription. ChIP analysis at varying times during this process would trap the 
complexes at a specific stage of promoter development giving the impression of a 
statically bound complex, although the actual dynamics of site occupancy are rapid  (see 
illustration of this “return to template” model in (Hager et al., 2006)). The rapid cycling 
of factors on and off its template allows promoters to be activated very rapidly upon 
stimulation, an obvious advantage for efficient promoter function.  
In addition to this dynamic cycling of factors on and off its regulatory element, detailed 
studies using ChIP analysis of ER responsive promoters have revealed a periodic cycling 
of ER and cofactors on the promoter over periods in the range of 15-45 minutes (Shang et 
al., 2000; Burakov et al., 2002; Metivier et al., 2003; Reid et al., 2003). Using an ultrafast 
UV crosslinking assay, a similar periodic binding and displacement of GR from its 
chromatin template was also observed in an in vitro system (Nagaich et al., 2004b). The 
underlying mechanisms and the significance of this cyclical behavior are at present 
unknown. It has been suggested that proteasome-mediated degradation of the receptor 
and phosphorylation of Pol II are important factors in this process (Reid et al., 2003). 
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Figure 5. Hit-and-Run model for nuclear receptor action
Upon ligand-binding, the nuclear receptor (NR) is translocated to the nucleus where it is 
associated with target sites in the chromatin. Factors of the transcriptional machinery are 
recruited, including chromatin remodeling complexes (SWI/SNF), histone acetyl transferases 
(CBP), coactivators (SRC) and RNA Polymerase II (PolII). The chromatin is remodeled, allowing 
for more proteins to bind and a fruitful transcriptional initiation complex is established. NR is 
dynamically displaced (symbolized by the arrows) and shuttles between the chromatin-bound and 
free nucleoplasmic state. 
2.2. Chromatin remodeling and chaperone dependency 
In addition to highly dynamic protein-chromatin interactions, emerging evidence suggests 
that energy-dependent processes contribute significantly to the rapid movement of 
proteins in live cells, and to the rapid exchange of sequence-specific DNA-binding 
proteins with regulatory elements. This was demonstrated by a strong ATP-dependence 
on factor movement, as ATP-depletion inhibited protein movement in the nucleus, as 
well as site specific interactions with a template (Elbi et al., 2004; Stavreva et al., 2004; 
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Agresti et al., 2005). Two separate energy-dependent mechanisms have been implicated 
in transcription factor mobility: chromatin remodeling and chaperone dependency. 
ATP-dependent chromatin remodeling complexes play essential roles in the regulation of 
transcription, DNA repair, cell cycle and development (Wallberg et al., 2000; Narlikar et 
al., 2002; Peterson, 2002; Gregory & Shiekhattar, 2004). According to the ATPase that 
forms the main component of the complex, they can be classified into three major types: 
SWI/SNF, ISWI, and Mi-2. The mammalian SWI/SNF complex is probably the best 
described, and was first identified in yeast (Peterson et al., 1994). It contains one of two 
ATPases, BRG1 or BRM, and several BRG1-associated factors. Even though BRG1 and 
BRM are highly homologous ATPases, they can play roles in very different cellular 
pathways through selective association with certain coregulatory proteins (Hsiao et al., 
2003; Kadam & Emerson, 2003; Salma et al., 2004). Although BRG1 has been shown to 
be the preferred ATPase for GR-induced (Fryer & Archer, 1998) and PR-induced 
(Mymryk & Archer, 1995) chromatin remodeling, a strong dependence for BRM as the 
core ATPase for AR activity has been demonstrated (Marshall et al., 2003). SWI/SNF is 
recruited to the AR transcription site via the histone acetyl transferases (HATs) CBP and 
p300. Although histone acetylation enhances the recruitment of SWI/SNF, it is not 
required for SWI/SNF-induced chromatin remodeling. However, both SWI/SNF 
remodeling activity and CBP/p300 HAT activities are required for hormone dependent 
activation. Hence, there is not only direct recruitment by NR’s, but also cofactor-cofactor, 
and cofactor-histone interactions occurring at the active transcription site (Huang et al., 
2003).  
Receptor mobility is also dependent on the presence of chaperone proteins. Unliganded 
GR, PR and AR usually reside in the cytoplasm in complex with several chaperones, such 
as certain heat shock proteins (HSPs). It is thought that chaperones are important for the 
insertion of the steroid ligand into the hydrophobic environment of the receptor LBD 
(Pratt et al., 1996). Other functions of molecular chaperones were demonstrated by Elbi 
et al., using digitonin to permeabilize cells such that much of the free cytoplasmic protein 
of the cells is released (Elbi et al., 2004). Due to their size, GFP-labeled receptors (GR 
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and PR) were retained in the cytoplasm enabling the study of their motility by FRAP 
analysis. Under conditions where the cells were permeabilized, the steroid receptors were 
totally immobile, but this loss was in large part recovered when a cocktail of seven 
chaperone proteins was added to the cells (Elbi et al., 2004). This process was also 
completely ATP-dependent. These results suggest a more general role of chaperones in 
NR action: chaperones are not only required for ligand assimilation but also the 
movement of receptor within the nucleus. 
2.3. Histone acetylation 
In addition to chromatin remodeling complexes, enzymes that catalyze posttranslation 
modifications of histones also regulate the accessibility of promoters to the transcription 
and replication machinery (Berger, 2002). Changes in the multiple modifications of the 
N-terminal tails of histones can control chromatin packaging and create binding-sites for 
chromatin-associated proteins (Jenuwein & Allis, 2001; Fischle et al., 2003). Several 
different covalent modifications of histones have been identified: acetylation (of lysine 
residues), methylation (of lysine or arginine residues), phosphorylation (of serine 
residues) and ubiquitination (of lysine residues) (for review see (Berger, 2002)). Histone 
modification and ATP-dependent chromatin remodeling are functionally connected for 
gene regulation, although it is unclear whether there exists an actual mechanistic 
interrelationship between them. Promoters are usually envisioned to be in either a non-
accessible off-state, or in a more accessible on-state allowing gene transcription. 
However, it now seems that genes pass through a continuum of activity states, and the 
evolution of these states can be quite complex (reviewed in (Hager et al., 2006)). 
Histone acetylation is one of the most well studied histone modifications. In general, 
histone acetylation induces transcription by converting chromatin from a low-acetylated, 
‘closed’ form, to an acetylated, ‘open’, more accessable form (Verdone et al., 2005). The 
key observation to support this view was that several promoter-associated coactivators 
possessed HAT activity, suggesting that HAT activity was important for transcriptional 
activation (Kuo & Allis, 1998). Several enzymes with HAT activity have been identified, 
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many of which are components of large multisubunit complexes, recruited to promoters 
by interaction with DNA-bound activator proteins.  
HAT activity is required for optimal AR activity. CBP, a well described histone 
acetyltransferase, was identified as a coactivator for AR, and the overexpression of CBP 
was also able to rescue the activity of transcriptionally compromised AR mutants 
(Fronsdal et al., 1998). Furthermore, AR agonists and antagonists exhibit differences in 
their ability to promote recruitment of HAT complexes to promoters, indicating that 
receptor-binding to chromatin is followed by histone modifications (Kang et al., 2004). In 
support of this, it was demonstrated by ChIP analysis that both CBP and the related p300 
were recruited to the promoter and enhancer of PSA gene by agonist-bound AR (Shang et 
al., 2002; Wang et al., 2005b). However, in the presence of the antagonist bicalutamide, 
CBP was not recruited, confirming the important role of HAT activity in AR 
transcriptional activation (Shang et al., 2002). Other AR coactivators possessing HAT 
actvtivity include SRC-1 and SRC-3 (also called AIB1, pCIP, and TRAM1) that interacts 
with CBP (Liao et al., 2002), and PCAF (p300/CBP associated factor), also involved in 
interaction with p300/CBP and in the acetylation of non-histone targets such as various 
transcription factors and also AR itself (Fu et al., 2000). 
2.3.1. HDAC inhibitors 
Enzymes called Histone Deacetylases (HDACs) function in opposition to HATs by 
deacetylating histone tails. In general, HDACs create a “closed”, non-accessible form of 
chromatin, inhibiting transcription of many genes, and are commonly associated with 
transcriptional repression (reviewed in (Marks et al., 2003)). At present, there are eleven 
identified HDACs in humans which can be divided into four classes based on sequence 
homology to yeast HDACs: class I (HDAC 1, 2, 3, and 8), class II (HDAC 6 and 10), 
class III (HDAC 4, 5, 7, and 9), and class IV (HDAC 11). The global chromatin 
acetylation status is dependent upon the correct equilibrium between HAT and HDAC 
activity. Genetic abnormalities in HAT/HDAC genes may cause an inbalance in 
chromatin acetylation status resulting in repression of, e.g. cell cycle control genes, or 
overexpression of oncogenes, which may promote tumorigenesis and cancer. If the 
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inbalance in histone acetylation is a result of inhibited HAT activity or increased HDAC 
activity, HDAC inhibitors (HDACis) may restore this balance and thereby block tumor 
cell proliferation. A variety of agents, both natural and synthetic, with HDACi activity 
have been discovered, and can be divided into five main classes: short-chain fatty acids, 
hydroxamic acids, electrophilic ketones, cyclic tetrapeptides, and amino benzamides (see 
Table 2). Genes silenced in cancer cells, such as many tumor suppressor genes, seem to 
be especially sensitive to HDACis. Interestingly, HDACis are growth suppressive and 
apoptotic only in transformed cells. They act very selectively, and alter the transcription 
of fewer than 2% of expressed genes. Many HDACis have therefore been explored for 
potential anti-cancer activity, and some of these are in clinical trials for cancer treatment 
(reviewed in (Monneret, 2005; Gallinari et al., 2007)). 
Although the general effect of HDACis is to increase acetylated chromatin and the 
resulting activation of several genes, there  are several examples where HDACs appear to 
be required for gene activation, and HDACis then actually repress gene transcription 
(Lallemand et al., 1996; Siavoshian et al., 2000; Laribee & Klemsz, 2001; Ferguson et 
al., 2003; Qiu et al., 2006). The effect of HDACis may also be dependent on the promoter 
and transcription factor context. This is exemplified by the MMTV promoter, at which 
the GR activity is inhibited upon treatment with the HDAC inhibitor TSA, in contrast to 
AR which is activated (List et al., 1999a; List et al., 1999b).  
2.3.2. HDAC inhibitors in prostate cancer 
A number of HDACis have proved to have antiproliferative effects in cultured human 
prostate cancer cells and in mouse xenograft models. The mechanisms by which these 
inhibitors exhibit their antiproliferative effect vary widely among the inhibitors. The 
hydroxamic acid pyroxamide caused growth inhibition through cell cycle arrest in 
prostate cancer cells, and inhibited the growth of the CWR22 prostate cancer xenografts 
(Butler et al., 2001), as did also its analogue SAHA (Butler et al., 2000), both with 
relatively low toxicity.  
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Table 2. Natural and synthetic HDAC inhibitors and their properties 
HDAC inhibitor Type Activity Clinical trials References 
AN-9 (pivaloyloxymethyl 
butyrate) Short-chain fatty acid H, C, A Phase I/II 
(Zimra et al., 1997; 
Reid et al., 2004) 
CI-994 Synthetic benzamide derivate  H, C, A Phase I 
(LoRusso et al., 1996; 
Loprevite et al., 2005) 
Depsipeptide 
(FK228/FR901228) 
Natural (bacterial) 
cyclic tetrapeptide H, C, A Phase II 
(Furumai et al., 2002; 
Piekarz et al., 2006) 
LAQ-824 Synthetic hydroxamic acid derivate H, C, A Phase I 
(Catley et al., 2003; 
Kato et al., 2007) 
MS-275 Synthetic pyridyl carbamate derivative H, C, A Phase II 
(Lee et al., 2001; Gojo 
et al., 2006) 
Na-Butyrate Short-chain fatty acid H, C, A Phase I/II (Prasad, 1980; Newmark et al., 1994) 
Na-Phenylbutyrate Short-chain fatty acid H, C, A Phase I (Gore et al., 2002; Camacho et al., 2007) 
PXD101 Synthetic hydroxamic acid derivate H, C, A  Phase I 
(Plumb et al., 2003; 
Qian et al., 2006) 
Pyroxamide Hydroxamic acid H, C, A - (Butler et al., 2001) 
Suberoylanilide 
hydroxamic acid (SAHA) 
Synthetic hydroxamic 
acid H, C, A Phase II 
(Vrana et al., 1999; 
Ruefli et al., 2001; 
Duvic et al., 2007) 
Trapoxin Natural (fungal) cyclic tetrapeptide H, C - (Kijima et al., 1993) 
Tributyrin Short-chain fatty acid H, C, A Phase I 
(Chen & Breitman, 
1994; Conley et al., 
1998) 
Trichostatin A (TSA) Natural (fungal) hyroxamic acid H, C - 
(Yoshida et al., 1987; 
Yoshida et al., 1995) 
Valproic acid Short-chain fatty acid H, C, A Phase I/II (Gottlicher et al., 2001; Kuendgen et al., 2005) 
H-inhibits purified HDAC 
C-inhibits growth of transformed cells 
A-inhibits in vivo tumor growth in animal models 
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Valproic acid, another hydroxamic acid, inhibited prostate cancer cell growth, in vitro
and in vivo, by inducing apoptosis (Angelucci et al., 2006; Xia et al., 2006). In a similar 
manner, sodium butyrate and TSA synergize with 1,25-(OH)-vitamin D3 to inhibit the 
growth of LNCaP, PC-3 and DU145 by inducing apoptosis (Rashid et al., 2001). The 
short chain fatty acid phenylbutyrate inhibited the invasive properties of prostate cancer 
cells (Dyer et al., 2002) and inhibited prostate cancer cell and xenograft proliferation 
through cell cycle arrest and induction of apoptosis (Melchior et al., 1999). The cyclic 
tetrapeptide depsipeptide (FK228) inhibited prostate cancer cell growth in vitro and in 
vivo, through the effect on the expression of angiogenesis factors (Sasakawa et al., 2003a; 
Sasakawa et al., 2003b). Possibly the most promising current HDACi is SAHA, which at 
doses without detectable toxicity, reduced tumor growth by 97% in mice transplanted 
with CWR22 human prostate tumors (Butler et al., 2000). It is also the most advanced 
HDACi in clinical trials, with meaningful clinical responses in patients with different 
types of cancer (Gallinari et al., 2007). However, there is at present no HDACi in clinical 
trials for prostate cancer. 
3. Androgens in Prostate Cancer 
Even before the discovery of testosterone, it was very well known that there was a strong 
dependency between the testes and the prostate. As early as 1895, reports showed the 
inverse correlation between prostate size and castration in elderly men. After the isolation 
of testosterone in 1934, Huggins and Hodges demonstrated that androgens, secreted from 
the testes, are important for the development and growth of prostate cancer (Huggins, 
1941). It is now clear that androgens have a critical role in the development and 
maintenance of the male reproductive system and have roles in physiological and 
pathological conditions, including the normal prostate and prostate cancer (reviewed in 
(So et al., 2003; Karayi & Markham, 2004)). 
3.1. Androgens in prostate biology 
The prostate is an exocrine gland of the male mammalian reproductive system. Its main 
function is to store and secrete a clear, slightly basic fluid that constitutes up to one-third 
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of the volume of semen. Some of the proteins contained in the prostate secretion helps 
liquefy the semen. However, the specific function of the prostate gland is still unknown, 
and it is in fact the largest organ of the human body of unknown specific function (Isaacs, 
1994). In the fetus, testosterone stimulates budding of the prostate epithelium from the 
urogenital sinus and signals the differentiation and growth of the prostate gland. If 
sufficient levels of testosterone are not present, the prostate gland does not develop. The 
prostate remains small (1-2 grams) until puberty when it grows to its adult size of 
approximately 20 grams. This period of exponential growth between the age of 10-20 
years is the same period when serum testosterone levels are rising from the initial low 
levels to the high levels seen in the adult male (Isaacs, 1994). When the adult size of the 
prostate is reached, there is normally no more net growth of the gland.   
The normal adult prostate gland shows a high degree of cellular organization, and is 
composed of a glandular epithelial and a fibromuscular stroma compartment. The 
epithelial compartment is made up of two major morphologically distinct cell types: the 
luminal and basal cells. Luminal cells tend to be differentiated and androgen dependent, 
with a relatively low proliferative capacity and high apoptotic index, while the basal cells 
generally appear undifferentiated and androgen independent, with high proliferative 
capacity and low apoptotic index, attributes characteristic of stem cells. The prostate 
epithelium has also a third cell type, the neuroendocrine cells, which are scattered at low 
percentage throughout the gland. In addition, a transiently proliferating/amplifying cell 
population, serving as an intermediate between the undifferentiated stem cells of the 
basal layer and the highly differentiated exocrine, and also neuroendocrine, cells of the 
lumen has been proposed (Isaacs & Coffey, 1989).  
3.2. Prostate carcinogenesis 
Androgen levels increase in puberty, resulting in a net growth of the prostate until it 
reaches its maximum adult size around the age of 20. After this age, the prostate normally 
ceases its continuous net growth, and androgens regulate the total number of prostatic 
cells by stimulating the rate of proliferation and at the same time inhibiting cell 
death/apoptosis (Isaacs, 1994). An inbalance in this regulation, either by increased 
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proliferation or inhibited apoptosis, may give rise to an abnormal growth of the prostate, 
eventually leading to prostate cancer.  
Carcinoma of the prostate is the most frequently diagnosed non-cutaneous malignancy in 
men.  It accounts for one third of all cancers diagnosed and it is the third leading cause of 
cancer-related death in men in western industrialized countries (Jemal et al., 2007). 
Prostate cancer is predominantly a disease of elderly men, with a steeply increasing 
incidence in the 7th decade of life. The recently observed rise in incidence of prostate 
cancer may, therefore, partly be explained by an ageing population. However, the age-
adjusted incidence has also increased, hence other factors such as genetic disposition, life 
style and diet are probably also important factors (Parkin et al., 2001). There is a striking 
difference in prostate cancer risk between ethnic groups, with a more than 10-fold higher 
incidence of prostate cancer in Western industrialized countries compared to East Asian 
countries (Quinn & Babb, 2002b; Quinn & Babb, 2002a). Furthermore, in the United 
States, the risk of prostate cancer is approximately 60% higher in African-American than 
in European-American men and the comparative mortality rate is more than twice as high 
(Powell, 2007). However, immigrant studies have demonstrated that genetic disposition 
can only account for some of this difference, suggesting that other factors, such as life 
style and diet, are important (reviewed in (Jankevicius et al., 2002)). In contrast to the 
increasing incidence of prostate cancer, the mortality rate has declined since the early 
1990s, possibly due to the use of PSA (Prostate Specific Antigen) screening leading to 
earlier diagnosis and treatment (see also paragraph 4.3). However, it is still debatable if 
the decline in mortality rate is actually a consequence of PSA screening (Constantinou & 
Feneley, 2006). Another reason could be a mis-certification of cause of death in a large 
group of men in the 1980s-1990s (Feuer et al., 1999). 
During the progression of prostate cancer (see Figure 6), the prostate retains some of its 
glandular structure and is therefore classified as adenocarcinoma. The first detectable 
morphological change in the development of prostate cancer is considered to be prostatic 
intraepithelial neoplasia (PIN). PIN may occur in men in their twenties (Isaacs, 1994), 
and can be detected histologically by thickening of the epithelial layer, and also loss of 
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distinct basal and secretory layers. The progression of the disease is slow, and clinically 
detectable prostate cancer does not typically arise until the sixth decade. The carcinoma is 
firstly confined to the prostate, but about one third of prostate tumors become locally 
invasive, spreading beyond the tissue capsule, and finally developes into metastatic 
disease (Isaacs, 1994). The most frequent metastatic sites for prostate carcinomas are 
bone, liver and lung, and the metastases usually appear undifferentiated. Most prostate 
cancer tumors regress upon initial androgen depletion therapy; however, the tumors in 
most cases recur in an androgen independent state for which there is no efficient therapy 
at present. The molecular mechanisms of transition from androgen-dependence to 
androgen-independence remain poorly understood, although it appears that AR signaling 
remains important throughout the course of the disease (Balk, 2002; Chen et al., 2004). 
For the last decade, there has been a major research focus on the molecular mechanisms 
of this transition which is crucial for the development of effective therapies (for reviews, 
see (Feldman & Feldman, 2001; Navarro et al., 2002; Agoulnik & Weigel, 2006)). 
Figure 6. Prostate cancer progression 
The epithelium of the prostate gland is composed of luminal cells (grey) oriented towards the 
lumen of the gland, basal cells (brown) and neuroendocrine cells scattered throughout the gland. 
In prostatic intraepithelial neoplasia (PIN), the cells start to proliferate towards the lumen of the 
gland, until the tissue capsule breaks and the tumor becomes locally invasive. The tumor then 
progresses to a metastatic state spreading to distant organs, and then finally to an androgen-
independent state.  
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3.3. Anti-androgens in prostate cancer treatment 
The initial treatment of prostate cancer is usually radical prostatectomy or radiation to 
remove or destroy the cancerous cells that are still confined within the prostate capsule. 
However, many patients are not cured by this treatment and their cancer recurs, or the 
patient may not have been diagnosed until after the cancer has spread beyond the tissue 
capsule (Pirtskhalaishvili et al., 2001). The first systemic therapy for advanced prostate 
cancer emerged in 1941 with the discovery that surgical or medical castration, leading to 
a reduction in the levels of circulating androgens, caused regression of prostate tumors 
(Huggins, 1941). This induced reduction in androgen-levels is called androgen ablation 
therapy, which still is the only successful treatment for advanced prostate cancer. There 
are several types of androgen ablation therapy: surgical castration, medical castration 
using LHRH analogues, anti-androgen monotherapy, and maximum androgen blockade 
(MAB) which is a combination of castration and anti-androgen administration. Surgical 
and medical castration lowers the levels of free testosterone in the circulation; however, 
some testosterone (~5%) still remains since androgens are also produced by the adrenal 
cortex, which is not affected by the treatment, and anti-androgens are then used to block 
the function of the remaining androgens (Pirtskhalaishvili et al., 2001; Anderson, 2003). 
Recently, monotherapy with anti-androgen alone have proved to be an attractive 
alternative to castration as it results in less severe side-effects (reviewed in (Anderson, 
2003)). Table 3 lists anti-androgens that were previously or are currently used in the 
treatment of advanced prostate cancer. The non-steroid antagonist bicalutamide is at 
present probably the most favorable anti-androgen used in prostate cancer therapy 
(Anderson, 2003; Miyamoto et al., 2004). 
Table 3. Anti-androgens previously and/or currently used in prostate cancer treatment 
Anti-androgen Trade name Type 
Cyproterone Acetate (CPA) Androcur, Climen, Diane 35, Ginette 35 Synthetic steroid, partial antagonist 
Bicalutamide Casodex Non-steroid, pure antagonist 
Flutamide Eulexin Non-steroid, pure antagonist 
Nilutamide Nilandron Non-steroid, pure antagonist 
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3.4. Prostate cancer models 
In vitro cell culture is one of the most commonly used models in cancer research. For the 
study of prostate cancer, the androgen-sensitive cell line LNCaP is the most widely used 
model system (Horoszewicz et al., 1980). This cell line is cultured from a lymph node 
metastasis of a white Caucasian man. LNCaP cells express AR, but with a T877A 
mutation in the LBD which renders it more sensitive to a wider range of steroid ligands 
than wild type AR (Veldscholte et al., 1990; Veldscholte et al., 1992; Tan et al., 1997). 
Some androgen non-responsive prostate cancer cell lines, such as PC-3 (bone metastasis) 
(Kaighn et al., 1979) and DU145 (brain metastasis) (Stone et al., 1978) are also widely 
used. Other cell lines are also available, but many of these have proved to be either 
derivatives of the three mentioned cell lines, or of other non-prostatic cell lines, or are not 
freely available (van Bokhoven et al., 2003). The available cell lines also do not span the 
range of prostate cancer phenotypes. Primary cultures, of both malignant and normal 
epithelial prostate cells, are therefore also necessary. Technical improvements over the 
last decades have made the use of primary cultures more widespread, and there are now 
several primary cultures of human prostatic cells, representing the different stages of 
prostate cancer, but some hurdles remain for their routine use (for review, see (Peehl, 
2005)). Xenografts derived from human prostate cancer cell-lines, is another means of 
obtaining in vivo models for human prostate cancer. At present, various xenograft models 
representing the various stages of clinical prostate cancer, and also in some cases cell 
lines established from these, are available (reviewed in (van Weerden & Romijn, 2000)). 
Animal models, mainly mouse and rat, are widely used tools in cancer research. Despite 
the obvious anatomical differences between the mouse and human prostate, several 
mouse models have been developed which recapitulate many features of human prostate 
cancer (reviewed in (Abate-Shen & Shen, 2002)). The most commonly used model is the 
TRAMP (transgenic adenocarcinoma mouse prostate) mice, expressing SV40 viral 
oncogenes specifically in the prostate driven by the rat probasin promoter (Greenberg et 
al., 1995). The TRAMP mice develop high-grade PIN and/or prostate cancer within 12 
weeks of birth, and also ultimately develop metastases by 30 weeks. Androgen depletion 
results in decreased tumor incidence, as well as the subsequent appearance of androgen-
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independent disease (Gingrich et al., 1997). Thus, the TRAMP mice recapitulate many 
aspects of human prostate cancer and have given significant insights into the molecular 
mechanisms of prostate cancer development and progression. Other transgenic and 
knock-out mouse models have also been developed (for a review, see (Abate-Shen & 
Shen, 2002)). Especially useful knock-out models for prostate cancer have been the 
NKX3.1 (Bhatia-Gaur et al., 1999) and PTEN (Di Cristofano et al., 1998) models. 
Human NKX3.1 is localized to chromosomal region 8p21, a region which undergoes 
loss-of-heterozygosity (LOH) in ~80% of prostate cancers (He et al., 1997). However, 
there are discrepancies in the literature about how or if NKX3.1 expression is changed 
during prostate cancer progression (Bowen et al., 2000; Xu et al., 2000; Ornstein et al., 
2001; Korkmaz et al., 2004b; Bethel et al., 2006); thus, it is under debate if the NKX3.1 
gene is actually lost in the Chr8p21 deletion. PTEN maps to chromosomal region 10q23, 
a region that also undergoes LOH at advanced stages in many cancers, including prostate 
cancer (Di Cristofano & Pandolfi, 2000). The cooperativity between loss of NKX3.1 and 
PTEN has also been studied, and was shown to be restricted to the prostate, and 
importantly, the knock-out mice displayed carcinoma lesions that resemble early stages 
of human prostate cancer (Kim et al., 2002).  
Under physiological conditions, cancer cells reside histologically as three-dimensional 
organoids, and the host microenvironment is known to be pivotal to malignant 
progression of the cancer cells (Chung et al., 2005). The established in vitro models do 
not fully recapitulate the prostate tumor environment, and further insight into cancer 
biology and therapy requires new and improved research models. Recently, several 3D 
co-culture models for the study of prostate cancer growth have been developed (reviewed 
in (Wang et al., 2005c)). Formation of human prostate tissue from embryonic stem cells 
which shows species–conserved signaling mechanisms, was also recently achieved 
(Taylor et al., 2006). These model systems may prove useful for studies of human 
prostate development and maturation and may give insights into mechanisms of prostate 
carcinogenesis. 
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3.5. Prostate cancer biomarkers 
As the treatment options for advanced prostate cancer are limited, early detection of the 
disease is essential. A biomarker that allows for the detection of prostate cancer at an 
early stage is therefore of significant importance, and much effort has been invested in 
the search for prostate specific molecules that might serve as cancer biomarkers or as 
therapeutic targets. AR regulated genes have been of special interest, which led to the 
discovery of PSA (Prostate Specific Antigen), a widely used biomarker for prostate 
cancer (see paragraph 4.3). Although increased levels of PSA are correlated with risk of 
prostate cancer, PSA has its limitations both for the detection and grading of prostate 
cancer due to high rates of false positive and negatives, and therefore other more specific 
markers are needed for the improved diagnosis and monitoring of disease progression. In 
this regard, other AR target genes have been of interest and the advances in microarray 
technology over the last decade have accelerated the insight into AR-mediated gene 
expression programs (see e.g. (DePrimo et al., 2002; Nelson et al., 2002; Nantermet et al., 
2005; Asirvatham et al., 2006)). The majority of large-scale expression studies have been 
performed in LNCaP cells, and gene expression profiling studies have revealed that 1.5% 
to 4.3% of the LNCaP transcriptome is either directly or indirectly regulated by 
androgens (for a review, see (Dehm & Tindall, 2006)). How these changes translate to 
the protein levels in most cases remains unclear, and is a subject of future research.  
4. Human Tissue Kallikreins 
The human tissue kallikreins (KLKs) is a family of proteins primarily expressed in the 
glandular epithelia of many organs, also the prostate. Their transcription is in many cases 
regulated by sex steroid hormones, which are involved in the development of several 
endocrine-related tumors. The most well studied member of this family is KLK3 or PSA, 
which is, as already described, a commonly used marker for prostate cancer. Other 
members of this family are also under scrutiny as potential biomarkers for prostate cancer 
and other endocrine-related cancers (reviewed in e.g. (Borgono & Diamandis, 2004)). 
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4.1. The human tissue kallikrein locus 
The human KLKs form a family of 15 closely related serine proteases encoded by 
conserved genes tandemly located in a large gene cluster (320 kb) on chromosome 
19q13.4 (Figure 7). The first three members of the family, KLK1 (tissue kallikrein), 
KLK2, and KLK3 (PSA) were long thought to be the only members of the family. 
However, during the last decade the availability of human genome sequences and 
extensive screening of the KLK locus has revealed the presence of 12 additional KLK 
genes (Riegman et al., 1992; Gan et al., 2000; Clements et al., 2001). This gene cluster 
represents the largest cluster of contiguous protease genes in the human genome (Puente 
et al., 2003; Yousef et al., 2003). The human KLK locus has its rodent counterpart with a 
cluster of 28 functional genes in mouse (Evans et al., 1987; Olsson & Lundwall, 2002) 
and 10 functional genes in rat (Southard-Smith et al., 1994), and tissue KLKs have to 
date been identified in six mammalian orders. The significance of the different numbers 
of KLK genes in the different organisms is currently not known. Alternative splicing is 
prevalent within the human KLK locus, a trait not observed with rodent genes, and 
alternative splice variants have been described for all but one (KLK14) of the KLK genes 
(reviewed in (Kurlender et al., 2005)). 
Figure 7. The human tissue kallikrein gene locus 
Position and orientation of the kallikrein genes KLK1-KLK15 in the KLK gene locus at 
Chr19q13.4, with genes with telomeric to centromeric orientation in green, centromeric to 
telomeric orientation in blue, and pseusogenes in red. Non-kallikrein genes are in grey.  
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4.2. Kallikreins as cancer biomarkers 
With the complete description of the human KLK locus, the main research effort is now 
centered around the elucidation of potential biological functions of the KLKs. The KLK 
genes encode putative serine proteases, with a conserved catalytic triad made up of 
histidine (H), aspartic acid (D) and serine (S), giving trysin- or chymotrypsin-like 
specificity. In vitro studies have shown that some KLKs can auto-activate while others 
can activate each other, suggesting that the KLKs may be part of an enzymatic cascade 
(Yousef & Diamandis, 2002; Borgono & Diamandis, 2004). Serine proteases play key 
roles in diverse physiological processes and vary widely with respect to substrate 
specificity (Rawlings & Barrett, 1993). The KLKs are expressed in a wide range of 
tissues, suggesting a functional role in diverse physiological and pathophysiological 
processes, including skin desquamation and other skin diseases, tooth development and 
enamel defects, Alzheimer’s disease, and Parkinson’s disease, in addition to several 
cancers. Hence, many members of the KLK family have shown potential as diagnostic or 
prognostic markers, especially in hormone dependent cancers such as prostate, breast, 
testicular and ovarian cancer (for reviews, see (Diamandis & Yousef, 2002; Borgono & 
Diamandis, 2004; Clements et al., 2004; Paliouras et al., 2007)). It has been suggested 
that KLKs might promote or inhibit cancer cell growth, angiogenesis, invasion and 
metastasis by activation of growth factors and other proteases, release of angiogenic or 
anti-angiogenic factors, and degradation of the extracellular matrix (ECM) (reviewed in 
(Borgono & Diamandis, 2004)). As KLKs possibly promote tumor growth through their 
proteolytic activity, the design of KLK inhibitors that may have potential in anticancer 
therapies is under development. For instance, highly specific serpins to KLK2 have been 
designed which displayed unique reactivity to KLK2 (Cloutier et al., 2004). Further 
research is required to reveal the functional roles of KLKs in various tissues and 
determine whether they have clinical utility as biomarkers for disease states, and possibly 
also as therapeutic targets.  
4.3. Prostate Specific Antigen (PSA) 
PSA is a widely used clinical tumor marker for detection and monitoring of prostate 
cancer progression (Stamey et al., 1987; Partin et al., 2002; Stephan et al., 2002). PSA is 
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produced at very high concentrations by the prostate gland, and it is secreted into the 
seminal plasma at a concentration from 0.5 to 5 mg/mL under normal physiological 
conditions. PSA degrades the seminal vesicle proteins semenogelin I and II and aids in 
the liquefaction of the semen, an event that is integral to sperm motility (Ban et al., 1984; 
Lilja, 1985; Lilja et al., 1989). Prostate cancer and physical trauma to the prostate, 
resulting in the perturbation of the prostate gland, can result in significant rise in the PSA 
concentration of the blood. Thus, elevated PSA levels are used as a marker for prostate 
gland abnormalities (Stephan et al., 2002; Lilja, 2003). 
The advantages of using PSA as a prostate cancer marker is that it is secreted and enters 
the circulatory system, allowing easy detection of PSA in patient’s serum samples. In 
addition, virtually all primary prostate tumors maintain PSA expression. However, there 
are some problematic issues concerning the use of PSA as a marker for prostate cancer. 
Due to PSA expression in benign prostatic hyperplasia (BPH), it is difficult to 
discriminate between BPH and prostate cancer, resulting in a high level of false positives 
and unnecessary biopsies (Barak et al., 1989; Drago et al., 1989). Another problem is that 
PSA can fail as a marker for residual disease since not all metastases maintain PSA 
expression (Sissons et al., 1992; Daher & Beaini, 1998; Constantinou & Feneley, 2006). 
Thus, the necessity to find additional markers for prostate cancer still remains.  
In addition to PSA, another gene of this family that is androgen regulated and highly 
enriched to prostate for expression is KLK2, which may also have utility as a prostate
cancer marker in conjunction with PSA (Rittenhouse et al., 1998; Stenman, 1999; 
Stephan et al., 2005). KLK2 is of particular interest in the discrimination of benign and 
malignant disease when the PSA levels are low, and between locally advanced and organ-
confined prostate cancer (Haese et al., 2005). Yet another member of the family, KLK4, 
has more recently been identified as prostate-specific and androgen regulated, and is 
described in more detail below.
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4.4. Kallikrein 4 (KLK4) 
KLK4 was first cloned in 1999 by different approaches and is also known as prostase, 
KLK4-L1, PRSS17 and ARM-1 (Nelson et al., 1999; Stephenson et al., 1999; Yousef et 
al., 1999; Korkmaz et al., 2001). The KLK4 gene has the typical kallikrein gene structure, 
with five exons and four introns (Nelson et al., 1999; Stephenson et al., 1999) (see Figure 
8A). Initial computer analysis of the gene predicted a transcript encoded by all five 
exons, which would be translated into a pro-KLK4 of 254 amino acids (aa), with a 26-aa 
signal peptide that would result in an active protein of 224 aa after cleavage of the pro-
piece. However, extensive screening of cDNA libraries and RACE analysis did not 
permit the cloning of a 5’-extension with the putative first exon (Korkmaz et al., 2001). 
By the use of reverse transcriptase-PCR of mRNA from the prostate cancer cell line 
LNCaP and the androgen-dependent prostate cancer xenograft CWR22, the vast majority 
of KLK4 mRNA was found to have only four coding exons (Korkmaz et al., 2001). This 
transcript would thus give rise to a protein lacking the signal peptide that normally targets 
the protein for secretion, and was therefore the first member of the kallikrein family that 
was predicted to be intracellularly localized.  
The KLK4 gene gives rise to 8 different mRNA forms through alternative splicing and/or 
alternative transcription start sites and expected to give rise to at least 7 different protein 
moieties (reviewed in (Kurlender et al., 2005)). It is at present not clear which of these 
transcripts are most relevant to prostate cancer. There have been some reports suggesting 
to prove the secretion of KLK4, however with questionable validity. Based on a KLK4-
specific immunoassays, it was claimed that KLK4 is secreted into biological fluids 
(Obiezu et al., 2002; Obiezu et al., 2005). However, the specificity of the antibodies used 
in these studies was not verified, it was for instance not demonstrated that the antibodies 
detect endogenous KLK4 in prostate cancer cells. Furthermore, sample numbers are not 
high enough for proper statistical analysis. Another study reports the secretion of KLK4 
based on the presence of KLK4-specific antibodies in prostate cancer patient sera (Day et 
al., 2002), which is only indicative of the presence of secreted KLK4. Importantly, they 
were also not able to detect endogenous KLK4 in LNCaP cells, questioning the 
specificity of the antibody used. A more recent report analyzed the compartmentalized 
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expression of endogenous KLK4 in prostate cancer cell lines and prostate tissue, and 
found that the full-length KLK4 transcript and the exon-1 deleted transcript are expressed 
in prostate cancer, resulting in a cytoplasmic and a nuclear form of the KLK4 protein, 
respectively (Dong et al., 2005), confirming the presence of a nuclear KLK4 as proposed 
(Korkmaz et al., 2001). Although these data suggest that KLK4 may be expressed in two 
major isoforms (see Figure 8), more extensive analysis is required for the determination 
of which forms of KLK4 are expressed, and their relative importance, in prostate cancer. 
Figure 8. Structure of the KLK4 gene and two KLK4 protein isoforms 
(A) Exon/intron organization of the KLK4 gene. Two translational start sites (*), and the stop 
codon is indicated (arrow). (B) Structure of the two KLK4 protein isoforms detected in prostate 
cancer, encoded by the full-length KLK4 transcript (upper) and the exon 1-deleted transcript 
(lower). The signal peptide (SP) and pro-piece (PP) of the secreted KLK4 is given. The positions 
of the three amino acids of the conserved catalytic triad (H, D, S) are indicated. 
The biological function of human KLK4 is at present unknown. Strong evidence suggests 
that the murine and porcine KLK4 is involved in the regulation of enamel matrix protein 
processing and further function in defining structure and composition of enamel (Hu et 
al., 2002; Simmer & Hu, 2002; Nagano et al., 2003). Recent studies reported that 
mutations of KLK4 results in enamel defect (Stephanopoulos et al., 2005; Hart, 2006). 
Human KLK4 is highly prostate enriched, and is androgen regulated (Nelson et al., 1999; 
Korkmaz et al., 2001), which suggests that it may function in prostate or seminal plasma 
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similar to KLK2 and PSA. The full-length KLK4 transcript, encoding a secreted protein, 
has been used in several studies to express recombinant versions of KLK4 in order to 
examine its substrate specificity. Takayama and coworkers showed that a recombinant, 
chimeric form of KLK4 (ch-KLK4) in which the pro-piece of KLK4 was replaced by that 
of PSA to create an activation site susceptible to trypsin-type proteases, had a trypsin-
type substrate specificity (Takayama et al., 2001). In addition, ch-KLK4 also readily 
activated both pro-PSA and single chain urokinase-type plasminogen activator (scuPA, 
pro-uPA), and completely degraded prostatic acid phosphatase (PAP), indicating that 
KLK4 may have a role in the physiological processing of seminal plasma proteins, as 
well as in the pathogenesis of prostate cancer through its activation of pro-uPA 
(Takayama et al., 2001). In a recent report, it was demonstrated that the three-domain 
receptor of uPA, uPAR, is also a target for KLK4, cleaved in the D1-D2 linker sequence 
and, to a lesser extent, in its D3 juxtamembrane domain (Beaufort et al., 2006). These 
data suggest a role of KLK4 in modulation of the tumor-associated uPA/uPAR-system 
activity by either activating pro-uPA or cleaving the cell surface-associated uPA receptor.
Furthermore, recombinant KLK4 was reported to cleave extracellular matrix proteins, 
suggesting a role of KLK4 in tissue remodeling (Obiezu, 2006). However, there is at 
present not sufficient substrate and enzymatic evidence to support the notion that KLK4 
has a functional role in seminal liquefaction.  
In addition to these in vitro studies with recombinant protein, there have been a few 
studies trying to reveal the biological function of endogenous KLK4 in prostate cancer 
cells. Veveris-Lowe et al. showed that cytoplasmic KLK4, as well as PSA, increases cell 
migration when ectopically expressed in the prostate cancer cell line PC-3. This was 
associated with loss of E-cadherin and an increase of vimentin, suggesting an 
involvement of cytoplasmic KLK4 in the epithelial-mesenchymal transition, a crucial 
event in the progression of cancer to an invasive phenotype (Veveris-Lowe et al., 2005). 
Recently, a role of secreted KLK4 in prostate cancer metastasis to bone was also 
suggested, based on the dependency of KLK4-expression in the interaction between 
prostate cancer cells and osteoblasts in bone metastasis (Gao et al., 2007). These results 
suggest that the secreted form of KLK4 may have a role in prostate cancer development 
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and progression, although more studies are needed in order to elucidate its actual 
presence in biological fluids, and exact role in prostate cancer biology. It is at present no 
report on the biological function of nuclear KLK4. For a complete understanding of the 
role of KLK4 in prostate cancer development and progression, it is important to elucidate 
the relevance of the different forms of KLK4 expressed. The functional properties of the 
encoded protein(s) may then be elucidated in greater detail. 
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AIMS OF THE STUDY 
As detailed in the introduction, androgens are involved in important physiological and 
pathological processes, such as normal prostate biology and prostate cancer; however, the 
molecular mechanisms of androgen action remain largely unclear. The major aim of this 
study was thus to examine in greater detail the molecular mechanisms underlying 
androgen action in the cell. To this end, there were two main focus areas:  
1. Characterization of the androgen target gene KLK4 
2. Nuclear dynamics of AR-mediated transcriptional activation 
KLK4 has been identified as a prostate specific and androgen regulated gene, with 
potentially important functions in prostate cancer. Previous work suggested that KLK4 
may have a different gene structure than the other members of the kallikrein family; thus 
we set out to map the 5’ end of the KLK4 transcript in detail. The cellular localization of 
the encoded protein, as well as its androgen regulation in prostate cancer cells was 
studied. To elucidate the potential role of KLK4 in prostate carcinogenesis, we examined 
the expression levels of KLK4 in benign compared to malignant human prostate glands. 
Furthermore, the functional properties of KLK4 in prostate cancer cells were elucidated 
using adenovirus-mediated overexpression and siRNA technology. 
AR is a ligand-dependent transcription factor and the main mediator of androgen action 
in the cell. Thus, a detailed understanding of the mechanisms by which AR regulates 
transcription is essential for elucidating androgen action. We therefore investigated AR-
mediated transcription in detail, with a special focus on its interaction with chromatin in 
response to androgens and anti-androgens. To this end, we developed a system enabling 
the visualization of GFP-tagged AR when it is bound to its response element in living 
cells. We then used advanced fluorescence microcopy techniques to elucidate the nature 
of AR interactions with target sites, and correlated these interaction kinetics with the 
recruitment of factors of the transcriptional apparatus and the initiation of transcription. 
Finally, we investigated how HDAC inhibitors affect AR transcriptional activity and 
chromatin interaction dynamics in living cells.  
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SUMMARY OF PAPERS 
Paper I. Kallikrein 4 is a predominantly nuclear protein and is overexpressed in 
prostate cancer 
Kallikrein 4 (KLK4) is a member of the human tissue kallikrein family, consisting of 15 
closely related serine proteases. It was demonstrated by systematic PCR analysis that 
KLK4 has a gene structure differing from the rest of the family members. The putative 
exon one, encoding a signal peptide targeting the protein for secretion, is not part of the 
main KLK4 transcript, and KLK4 is thus an intracellular protein. Immunostaining of 
ectopically expressed KLK4 in COS-7 cells and endogenous KLK4 in LNCaP cells 
demonstrated that KLK4 is predominantly localized in the nucleus, which was further 
confirmed by biochemical fractionation experiments. KLK4 is strongly androgen-regulated 
in LNCaP cells, and is not expressed in the androgen-insensitive cell lines PC-3 and 
DU145, suggesting that KLK4 expression is correlated with the presence of functional AR. 
Furthermore, we showed that KLK4 mRNA is overexpressed in prostate cancer compared 
to normal prostate by in situ hybridization of prostate tissue microarrays, being expressed 
predominantly in the nucleus of basal cells of the prostate epithelium. This is the first 
report of nuclear localization of a member of the kallikrein family, suggesting that it may 
have unique functions compared to the other members of the family. Importantly, its 
androgen regulation and overexpression in prostate cancer suggest that it might have 
important roles in prostate carcinogenesis. 
Paper II. Ligand-specific dynamics of the androgen receptor at its response element in 
living cells  
Cell lines with tandem repeats of the MMTV promoter stably integrated into its genome 
have previously been used to demonstrate rapid interactions between steroid hormone 
receptors and chromatin in live cells. As the hormone response elements of the MMTV 
LTR function also as AREs, we adopted this system and established MMTV array 
containing cell lines stably expressing GFP-fusions of AR and a transcriptionally impaired 
mutant (AR-E897A). FRAP analysis in combination with other methods was used to study 
the dynamics of AR-chromatin interactions in live cells in response to a wide set of AR 
ligands. A rapid interaction of AR with target genomic sites in living cells in the presence
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 of agonists was demonstrated, which coincided with the recruitment of PolII and the 
SWI/SNF chromatin remodeling complex, resulting in transcriptional activation. The 
interaction of antagonist-bound or mutant AR with its target site was kinetically different: it 
was dramatically faster, and occurred without the recruitment of SWI/SNF or PolII, and 
without any transcriptional activation. ATP- and SWI/SNF-dependent displacement of AR 
from the MMTV chromatin was also demonstrated in vitro. Furthermore, FRET analysis of 
wild type and mutant AR, when associated with its target sites, showed that intramolecular 
interactions between the N- and C-termini of AR play a key functional role in AR 
transcriptional activation. These data provide a kinetic and mechanistic basis for regulation 
of gene expression by androgens and anti-androgens in living cells. 
Paper III. Kallikrein 4 is a proliferative factor that is overexpressed in prostate 
cancer 
As demonstrated in Paper I, KLK4 is a unique member of the human tissue kallikrein 
family. Here we further elucidate the functional properties of KLK4 in prostate cancer 
cells, and its expression in normal prostate and prostate cancer specimens. Firstly, we 
examined the expression of KLK4 at the protein level in prostate tissue microarrays by 
immunohistochemistry. Consistent with its mRNA expression, KLK4 is significantly 
overexpressed in malignant prostate carcinomas as compared to benign prostate glands. 
Furthermore, KLK4 is predominantly expressed in the nucleus of basal cells of the prostate 
epithelium. An adenovirus-mediated expression system for KLK4 was generated and used 
to conditionally express KLK4 in the prostate cancer cell lines PC-3 and DU145. The 
expression of KLK4 in these cell lines dramatically induced proliferation as demonstrated 
both by colony formation and proliferation assays. The increased proliferation was at least 
in part through significant alterations in cell cycle regulatory gene expression as 
demonstrated by cell cycle specific oligonucleotide array analysis. Consistent with these 
data, siRNA-mediated knockdown of endogenous KLK4 in LNCaP prostate cancer cells 
inhibited cell growth. These data identify KLK4 as the first member of the kallikrein family 
with proliferative properties mediated through the alteration of cell cycle regulatory gene 
expression, and indicate that KLK4 may have important roles in prostate cancer 
development and progression. 
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Paper IV. Reduced mobility of the androgen receptor at its target sites in living cells 
in response to histone deactylase inhibiton 
As reviewed in the introduction, histone acetylation is an important factor in gene 
regulation. Compounds that affect histone acetylation, such as inhibitors of histone 
deacetylases (HDACis), can thus be used to regulate gene expression. The mechanisms by 
which histone acetylation regulates transcription is unclear, hence we elucidated the effect 
of altered chromatin acetylation on the dynamic interactions between AR and chromatin as 
described in paper III. To this end, HDACis were used to induce AR transcriptional 
activity, and its corresponding nuclear mobility was examined by FRAP analysis. 
Furthermore, the mobility of a transcriptionally impaired AR mutant (AR-E897A), and also 
GR, was analyzed in a similar manner. We demonstrated that AR and AR-E897A mobility 
is strongly reduced in response to HDAC inhibitors TSA and SAHA, which correlated with 
increased transcriptional activity. However, TSA and SAHA did not affect mobility of 
antagonist bound AR and AR-E897A with no change in transcriptional activity. 
Importantly, the same inhibitors did not increase the transcriptional activity of agonist-
bound GR, and its mobility on the target promoter was not affected. These data suggest that 
histone acetylation is involved in the dynamic interaction between steroid receptors and 
target sites in chromatin through alteration of receptor transcriptional activation.  
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RESULTS AND DISCUSSION 
Kallikrein 4 is an intracellular protein that is overexpressed in prostate cancer  
Previous work from our laboratory (Korkmaz et al., 2001) suggested that KLK4 has a 
different gene structure than the other family members, with only four coding exons. The 
KLK4 main transcript was proposed to lack the putative exon 1, thus encoding a protein 
without a signal peptide, possibly resulting in an intracellular protein. This would suggest 
a different function of KLK4 compared to the other members of the kallikrein family, 
hence it was of significant importance to explore the nature of the KLK4 transcripts. 
We therefore set out to analyze the 5’ end of the KLK4 transcript in greater detail. 
Through a detailed PCR analysis using a set of different 5’-primers, it became evident 
that a transcript without the putative exon 1 was the physiological relevant form of KLK4 
mRNA. A transcript containing all five exons was also present, although at a 1000-fold 
less abundancy than the exon 1-deleted transcript. A transcript lacking the putative exon 
1 would encode a protein not targeted for secretion, and we therefore decided to examine 
the cellular localization of KLK4. Ectopic expression of tagged KLK4 in COS-7 cells 
showed predominantly nuclear localization of the protein. A KLK4-specific antibody was 
raised, and used to stain endogenous KLK4 in LNCaP cells, confirming the nuclear 
localization of the protein. Biochemical fractionation experiments furthermore confirmed 
the localization of KLK4 to the nucleus (Figure 9).  
The androgen regulation of KLK4 had been demonstrated at the mRNA level (Nelson et 
al., 1999; Yousef et al., 1999; Korkmaz et al., 2001). Having a KLK4-specific antibody, 
Western analysis was used to demonstrate androgen regulation also at the protein level, 
with a 20-fold increase in KLK4 after 48 hours of androgen treatment of LNCaP cells. 
No KLK4 was detected in the androgen-insensitive prostate cancer cell lines DU145 and 
PC-3, suggesting that KLK4 expression is correlated with the presence of functional AR. 
The fold-regulation of KLK4-expression upon androgen treatment has varied widely 
among different studies (Nelson et al., 1999; Stephenson et al., 1999; Yousef et al., 1999; 
Korkmaz et al., 2001; Dong et al., 2005), possibly due to differences in cell culture 
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conditions and antibody-specificity, and clearly also discrepancies in which KLK4 
isoform has been studied.  
Figure 9. Nuclear localization of KLK4 
(A) LNCaP cells were treated with R1881 for 48 hours and subjected to immunofluorescence 
analysis with a KLK4-specific antibody, or (B) nuclear (nucl.), cytoplasmic (cyt.), whole cell 
(WCE) and secreted (Med.) protein extracts were made and subjected to Western analysis using 
specific antibodies for KLK4, STAMP1, NKX3.1 and PSA. 
The size of the protein detected by Western blot was around 45 kDa, in contrast to the 
calculated size of about 28 kDa. This suggests that KLK4 may be post-translationally 
modified. However, despite thorough analysis no glycosylation modifications of KLK4 
could be detected, suggesting that KLK4 may be modified in other ways such as by 
ubiquitination or sumoylation. Further analysis is thus needed to determine the nature of 
KLK4 post-translational modifications. 
The prostate-specific, and androgen regulated expression of KLK4 suggest a potential 
involvement in prostate cancer. Hence, we used a KLK4-specific riboprobe to study 
KLK4 mRNA expression in prostate tissue microarrays, containing normal and tumor 
glands from human prostates. The analysis showed that KLK4 was significantly 
overexpressed in prostate carcinoma compared to benign prostate glands. Furthermore, 
KLK4 was predominantly expressed in the nucleus of the basal cells of the prostate 
epithelium. Together these findings confirm the presence of an intracellular form of 
KLK4, with potential function in prostate carcinogenesis.  
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The presence of an intracellular form of KLK4 has later also been confirmed by others 
(Dong et al., 2005). There are some discrepancies in the exact N-terminal sequence of the 
nuclear form of KLK4 which should be elucidated in future studies. Furthermore, Dong 
et al. did not detect any androgen regulation of nuclear KLK4 in LNCaP cells (Dong et 
al., 2005), in contrast to what has been repeatedly observed in our laboratory. The 
exchange of cells and antibodies between the laboratories might aid in elucidating the 
reason for this obvious discrepancy. In line with our observations, Dong et al. also did not 
detect any glycosylation of nuclear KLK4, proposing that the discrepancy between 
calculated and detected size of the protein is due to other modifications. 
Although the full-length KLK4 transcript was found to be much less abundant than the 
exon 1–deleted transcript, it cannot be ruled out that also the full-length transcript 
encodes a protein with important physiological roles. As discussed in the introduction, 
there have been some reports on the secretion of KLK4, however with questionable 
validity (Day et al., 2002; Obiezu et al., 2002; Obiezu et al., 2005). More recently, work 
by Dong et al, which confirmed the presence of a nuclear form of KLK4, also detected a 
cytoplasmic KLK4 in prostate cancer cell lines and prostate cancer tissue (Dong et al., 
2005). Furthermore, secreted KLK4 was also detected in seminal fluid from a prostate 
cancer patient, not present in a healthy individual. Later work from the same laboratory 
propose cytoplasmic KLK4 to have roles in epithelial-mesenchyme transition processes, 
indicating that it may be involved in the  progression of prostate cancer through the 
promotion of tumor cell migration (Veveris-Lowe et al., 2005). Furthermore, a recent 
report from Gao et al. suggests that secreted KLK4 potentially is involved in the cellular 
interaction between prostate cancer cells and osteoblasts, thus proposing a role of KLK4 
in prostate cancer bone metastasis (Gao et al., 2007). Taken together with the data 
presented in this thesis, it can be suggested that KLK4 is expressed in both a nuclear and 
secreted form. Both forms may have important function in prostate carcinogenesis, and 
their properties and relative importance in prostate cancer needs to be explored 
individually. 
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The abundancy of the exon-1 deleted KLK4 transcript, its overexpression in prostate 
cancer and its strong androgen regulation suggest a potentially important physiological 
role of nuclear KLK4 in prostate carcinogenesis. Thus we set out to elucidate its 
expression in prostate specimens, and its functional role in prostate cancer cells in greater 
detail. Firstly, we analyzed KLK4 protein expression in prostate tissue microarrays by 
immunohistochemical staining. The analysis confirmed the results at the mRNA level, 
with significant overexpression of KLK4 in malignant prostate carcinoma compared to 
benign prostate glands. This is also in line with what has been observed in another study 
(Veveris-Lowe et al., 2005), however in contrast to what was found by others (Obiezu et 
al., 2005). Both these studies examined the cytoplasmic and secreted form of KLK4, 
probably giving rise to the discrepancies. One study reports the expression of nuclear 
KLK4 in human prostate specimens, with stronger signal in cancer cells than in benign 
glands (Dong et al., 2005), however without any statistical analysis. This is therefore the 
first report of significant overexpression of nuclear KLK4 in prostate cancer. The 
immunohistochemical staining further confirmed the nuclear localization of KLK4, with 
expression predominantly in the basal cells of the prostate epithelium. 
KLK4 is a proliferative factor in prostate cancer cells 
To study the functional properties of KLK4 in prostate cancer cells, we developed an 
adenoviral-mediated expression system. The system was designed to express a His-
tagged KLK4 under a doxycycline-inducible promoter (Figure 10A). The proliferative 
effect of KLK4-expression in the prostate cancer cell lines PC-3 and DU145 was 
evaluated by colony formation and proliferation assays, and the results clearly 
demonstrated a proliferative effect of KLK4 in both cell lines (Figure 10B).  
Increased proliferation of cancer cells can be mediated through several mechanisms, such 
as inhibition of apoptosis or induction of cell cycle progression. To evaluate if the latter 
was the case in our system, cell cycle specific oligoarrays were probed with biotin-
labeled cRNA from KLK4-expressing PC-3 cells, and compared to non-expressing cells. 
The analysis revealed that the proliferative effect of KLK4 was at least in part through 
the alteration in cell cycle regulatory gene expression. Several genes involved in 
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progression of the cell cycle, such as E2F1 and cyclin B1, as well as the proliferative 
markers PCNA and Ki-67, were upregulated in response to overexpression of KLK4. 
Furthermore, several inhibitors of the cell cycle, such as the CDK (cyclin dependent 
kinase) inhibitors p15, p16 and p21, were downregulated in the same cells. CDK 
inhibitors act as tumor-suppressor genes, and their down-regulation or loss is commonly 
seen in prostate cancer (reviewed in (Fernandez et al., 2002)). These data suggest that 
KLK4 induces proliferation of prostate cancer cells through the alteration of cell cycle 
regulatory gene expression. As KLK4 is not a transcription factor, intermediate factors 
must be involved and the identification of these will give important information about the 
mechanisms of action of KLK4.  
                        
Figure 10. Overexpression of KLK4 induces proliferation of prostate cancer cells
(A) PC-3 and DU145 cells were infected with KLK4-expressing adenovirus, and the expression 
of His-tagged KLK4 upon addition of doxycycline was verified by Western analysis using a His-
specific antibody. (B) Quantification of colony formation by PC-3 and DU145 cells expressing 
(+dox) or not expressing (-dox) KLK4. p<0.05 as assessed by Student’s t-test. 
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The size of the adenovirus-expressed KLK4 was about 26 kDa, which is significantly 
smaller than the size of endogenous KLK4 in LNCaP cells (see Paper I), questioning if 
the physiological properties of KLK4 are maintained in this system. In addition, the 
overexpression of proteins may cause non-specific side-effects on cellular properties. 
Hence, in order to elucidate if the observed proliferative effect of KLK4 also applied to 
endogenous KLK4, siRNA was used to specifically knock down the expression of KLK4 
in LNCaP cells. The specific knock-down of KLK4 was confirmed both at the mRNA 
and protein level, and resulted in the inhibition of growth of the LNCaP cells. These 
results confirm the proliferative effect of KLK4 in prostate cancer cells, suggesting that 
the smaller size KLK4 expressed in PC-3 and DU145 cells has maintained its functional 
properties.
This is the first report on important biological functions of the nuclear form of KLK4. 
The data presented suggest a role of KLK4 in prostate cancer cell proliferation, proposing 
that KLK4 may be involved in the progression of prostate cancer. The specific 
mechanisms by which KLK4 mediates this effect remain to be elucidated 
Ligand-specific dynamics of the androgen receptor 
As detailed in the introduction, the traditional way of viewing nuclear receptor action has 
recently been challenged by a new dynamic model, in which the receptor transiently 
interacts with its target genomic sites and are dynamically displaced at the timescale of 
seconds (see Figure 5). The dynamics of AR interaction with target genomic sites have 
not previously been studied, thus we set out to analysie the kinetics of AR interaction 
with chromatin in respose to angonists and antagonists using advanced fluorescence 
microcopy techniques. 
Cell lines with integrated tandem repeats of the MMTV promoter, containing 800-1000 
binding sites for AR, stably expressing GFP-tagged AR and the mutant AR-E897A were 
generated. These cell lines have maintained their response to AR ligands with respect to 
nuclear translocation and transactivation potential. The high density of AR binding sites 
within the tandem MMTV repeat enabled the visualization of the GFP-tagged receptor 
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when bound to its response element, and FRAP analysis was used to analyze the 
dynamics of the interaction between the receptor and its promoter in living cells in 
response to agonists, partial antagonists and antagonists. The FRAP recovery curves 
(Figure 11A) clearly demonstrate a rapid and dynamic interaction between AR and its 
target promoter, with times for half-maximum recovery in the scale of seconds. The 
recovery of AR is strongly ligand-dependent, with significantly delayed recovery in 
response to agonist as compared to antagonist. The delayed recovery corresponds to 
increased AR transcriptional activity, as demonstrated by RNA FISH analysis (Figure 
11B). Furthermore, the recovery of the transcriptionally impaired mutant AR-E897A was 
significantly faster than wild type AR, proposing a correlation between AR 
transcriptional activity and recovery kinetics at the promoter. 
Figure 11. Ligand-specific dynamics of AR 
GFP-AR expressing cells were treated with different ligands as indicated, and GFP-AR 
interaction with the MMTV array was analyzed by FRAP analysis (A), or the cells were subjected 
to RNA FISH analysis for quantification of transcriptional activity (B). Error bars represent 
standard error. 
Rapid recovery of agonist bound-AR as demonstrated by FRAP analysis was first 
described by Farla et al. (Farla et al., 2004), and the recovery kinetics was later shown to 
be ligand-dependent with faster recovery of antagonist-bound AR than agonist-bound AR 
(Farla et al., 2005; Marcelli et al., 2006), in line with our observations. However, these 
studies were performed on AR in the general nucleoplasmic space, and not on a target 
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promoter. This is therefore the first time to demonstrate the transient and rapid interaction 
between AR and its response element in living cells. 
Delayed recovery of agonist-bound receptor as compared to unliganded receptor has also 
been demonstrated for the steroid hormone receptors PR (Rayasam et al., 2005) and ER 
(Stenoien et al., 2001b). As observed for AR, the recovery of PR was faster in the 
presence of antagonist (ZK98299) than in the presence of agonist (R5020) (Rayasam et 
al., 2005). In agreement with our observations, the partial antagonist RU486 resulted in 
delayed recovery of PR compared to the pure antagonist ZK98299, suggesting that the 
mechanism of RU486 induced antagonism is different from other antagonists. In contrast 
to what was observed for AR and PR, ER mobility was dramatically reduced in the 
presence of antagonist ICI 182,780 compared to agonist E2 (Stenoien et al., 2001b), 
suggesting that antagonist function differs among the steroid hormone receptors. 
The delayed recovery of agonist-bound AR coincided with the recruitment of Pol II and 
the chromatin remodeling complex SWI/SNF, which was not observed for antagonist-
bound AR or the mutant AR-E897A. Furthermore, in an in vitro chromatin remodeling 
assay, ATP- and SWI/SNF-dependent displacement of AR from the chromatin template 
was seen, demonstrating the importance of chromatin remodeling in the dynamic 
interaction between AR and chromatin. The involvement SWI/SNF-induced chromatin 
remodeling in transcriptional activation has previously been described for AR, as well as 
other nuclear receptors (Fryer & Archer, 1998; Dilworth & Chambon, 2001; Fletcher et 
al., 2002; Belandia & Parker, 2003; Marshall et al., 2003; Rayasam et al., 2005).  
As described in the introduction, an intramolecular interaction between the N- and C- 
termini of AR is important for optimal receptor activity, however, this interaction has not 
been demonstrated for AR in its active form when associated with its target genomic site. 
We therefore used FRET analysis of dual-labeled AR when bound to the MMTV array to 
examine the importance of this intramolecular interaction. The possible role of 
intermolecular interaction between two neighboring molecules was also evaluated. A set 
of AR and AR-E897A fusion proteins were generated, and their expected response to 
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androgen was confirmed by luciferase reporter assays. Acceptor photobleaching was then 
used for FRET analysis, and the results confirm the presence of intramolecular 
interactions between the N-and C-termini of wild type AR when associated with its target 
promoter (Figure 12). FRET was significantly reduced for the transcriptionally impaired 
AR-E897A, suggesting that the intramolecular interaction is important for optimal 
receptor activity. Some FRET was also observed when co-transfecting single-labeled AR 
(CFP-AR + AR-YFP), suggesting that there are some intermolecular interactions between 
neighboring molecules. However, these are similar for wild type and mutant AR, 
suggesting that they are not as important for AR transcriptional activity as the 
intramolecular interactions.  
Together these data give significant new information about mechanisms of actions of AR, 
and about antagonist function. The results support the hit-and-run model of nuclear 
receptor action, suggesting that the model describes a general feature of at least steroid 
hormone receptors, and possibly also of other DNA-interacting proteins. This dynamic 
nature of protein-chromatin interaction allows for very rapid response to changes in the 
cellular environment, giving a new dimension to transcriptional regulation.  
          
Figure 12. Intramolecular interactions of AR at its target promoter
(A) MMTV array-containing cells were transfected with different AR-fusion constructs as 
indicated, treated with R1881 for 48 hours, and subjected to FRET analysis. (B) Schematic 
presentation of the intramolecular interaction between the N-and C-termini of agonist-bound AR 
Error bars represent standard error, * means statistically difference (p<0.05) as assessed by 
Student’s t-test. 
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Reduced mobility of the androgen receptor in response to HDAC inhibitors  
As discussed in the introduction, histone acetylation is an important factor in gene 
regulation; however, the underlying mechanisms are unclear. Thus we wanted to 
elucidate the effect of altered chromatin acetylation on the dynamic interactions of AR 
with its target sites in living cells. HDACis are compounds that change the acetylation 
status of chromatin by inhibiting the deacetylation of histone tails, and it has been shown 
that AR transcriptional activity is induced by HDACis (List et al., 1999b; Shang et al., 
2002; Korkmaz et al., 2004a). Hence, we decided to use the HDACis TSA and SAHA in 
our system to study the effect of chromatin acetylation on AR interactions with 
chromatin, and the possible correlation between transcriptional activity and receptor 
dynamics. 
TSA treatment resulted in increasing acetylation of histone 3 (H3) in our cell lines in a 
time-dependent fashion, concomitant with an increase in AR transcriptional activity and 
delayed FRAP recovery curves (Figure 13). However, AR recovery dynamics was not 
affected by treatment with the same compound when associated with antagonist (OHF), 
corresponding with no change in transcriptional activity. The same effect was also seen 
for the HDAC inhibitor SAHA. Furthermore, TSA induced the transcriptional activity of 
the mutant AR-E897A, followed by significantly delayed FRAP recovery at the MMTV 
array. These data suggest that increased histone acetylation results in delayed recovery 
and increased residence times of AR at the promoter through the induction of 
transcriptional activity. 
HDAC inhibitors can have various effects on different receptors, and in different 
promoter contexts. In contrast to for AR, HDAC inhibitor TSA has actually been shown 
to have an inhibitory effect on GR activity on the MMTV promoter (List et al., 1999a). 
We therefore used a previously described (McNally et al., 2000) cell line with integrated 
MMTV array stably expressing GFP-GR to study the effect of HDAC inhibitors on GR 
nuclear mobility. TSA and SAHA had the same effect on chromatin acetylation status in 
this cell line as in the AR cell lines; however, GR transcriptional activity was not 
significantly altered in response to the inhibitors and FRAP analysis demonstrated no 
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change in GR residence time on the promoter. These data support a correlation between 
increased transcriptional activity and reduced nuclear mobility. Furthermore, the data 
suggest that histone acetylation does not always induce transcription, but is dependent on 
promoter and transcription factor context. A more detailed study into the factors involved 
in the dynamic exchange of the receptor between its chromatin-bound state and the free 
nucleoplasmic state will give further information about the mode of action of nuclear 
receptors. It will be of special interest to examine which factors are involved in AR-
mediated transcription in comparison to GR-mediated transcription, thereby identifying 
factors with receptor-specific roles. Potential candidates might be HDACs, which have 
shown to be exhibit both activation and repression properties as co-regulators for nuclear 
receptor action (Gallinari et al., 2007). One example is HDAC1, which has a repressive 
role in AR transactivation (Shang et al., 2002), while it has been identified as a 
coactivator for GR (Qiu et al., 2006).  
Figure 13. Increased transcriptional activity and reduced mobility of AR in response to 
HDAC inhibitor TSA 
GFP-AR expressing cells were treated with TSA and R1881 or OHF for different time periods, 
and subjected to RNA FISH (A) and FRAP (B) analysis. Error bars represent standard error, and 
* indicates statistically difference (p<0.05) as assessed by Student’s t-test. 
Together these data gives further insight into the molecular details of the dynamic 
interaction between AR and its target sites. Furthermore, important differences between 
AR- and GR-dependent transcriptional activation have been identified, being potentially 
important in the search for novel diagnostic and therapeutic targets in prostate cancer. 
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The proposed correlation between transcriptional activity and AR mobility on the 
promoter needs to be elucidated in greater detail, but could potentially be used as a tool in 
high-throughput screening for novel anti-androgens for the use in prostate cancer therapy. 
Detailed analysis of the dynamic interaction between nuclear receptors, and also other 
transcription factors, and chromatin are needed in order to fully understand the molecular 
details of transcriptional regulation. 
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FUTURE PERSPECTIVES 
In this thesis, we identified KLK4 as a unique, intracellular member of the KLK family. 
We found that KLK4 is overexpressed in prostate cancer and induces proliferation of 
prostate cancer cells, suggesting that it may have important roles in prostate 
carcinogenesis. The mechanism by which KLK4 achieves this effect is largely unknown 
and will be of importance to explore in greater detail. A comprehensive study of KLK4 
expression in prostate tissue specimens from large patient cohorts, representing the 
various stages of prostate cancer, would give clues as to how KLK4 expression varies 
during prostate cancer progression. The expression of KLK4 in matched normal and 
cancer samples from the same prostate gland would also be of interest to study to 
elucidate the local expression pattern of the protein. These data would give valuable 
information about the potential in using KLK4 as a diagnostic or prognostic marker for 
prostate cancer. 
One important aspect of KLK4 expression is its regulation by androgens; however, the 
fold induction of KLK4 by androgens has varied between different studies. The reason 
for this discrepancy should be explored. The KLK4 promoter should be analyzed for 
potential androgen response elements, and the functionality of these determined. To this 
end, and for other analysis concerning androgen regulation, it would be of great value to 
check the response of KLK4 expression in other androgen regulated cell lines, such as 
LAPC-4 (Klein et al., 1997). There is also inconsistency in the literature regarding the 
size of KLK4. Possible post-translational modifications of KLK4, such as glycolysation 
and sumoylation, and the physiological relevance of these, if any, are also important 
aspects to explore. To understand the potential role of KLK4 in prostate cancer, the 
specific mechanisms underlying the proliferative effect of KLK4 are of importance to 
elucidate. This can possibly be achieved through the identification of KLK4 interaction 
partners, and direct up- or downstream targets, both for ectopically expressed and 
endogenous KLK4. This can for example be achieved by yeast two hybrid analysis and 
co-immunoprecipitation studies. Furthermore, examination of the effect of KLK4 
expression in in vivo model systems, either by overexpression or knock-down/knock-out 
studies, would give valuable insight into KLK4 function. Given its intracellular location, 
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KLK4 likely has different functional roles than the other members of the KLK family. 
Possible nuclear variants of the other KLKs may also exist and needs to be explored in 
detail. The presence of the other KLK4 isoforms should also be explored, and the 
possible functional roles of these should be determined. Taken together, these studies 
would give important new information about KLK4 function and its possible role in 
prostate carcinogenesis.  
In this thesis we also explore the molecular mechanisms of AR action in living cells, 
using advanced fluorescence microscopy techniques. The data presented demonstrate a 
very dynamic interaction between AR and its target promoter, supporting the hit-and-run 
model of nuclear receptor action. The traditional static view on nuclear receptor-
chromatin interactions and the idea of a stable transcriptional complex staying bound to 
the template for as long as transcription occurs, is challenged by this model. Although a 
highly dynamic behavior has now been described for many nuclear proteins in the 
general nucleoplasmic space, it is essential that similar studies, as we present here for 
AR, for other transcription factors on their regulatory elements are performed. These 
studies would then decide if the observed behavior also applies to a wider range of DNA-
interacting proteins, or is specific for just a subset of transcription factors.  
The long-term loading profile of AR and its cofactors onto the MMTV promoter would 
be of interest to elucidate, by ChiP analysis, in order to determine if AR exhibits the same 
cyclical loading profile as observed for ER. The possible functional relevance of this 
could then be explored. The role of chromatin acetylation on receptor dynamics should 
also be elucidated in greater detail. HDAC inhibitors are important tools for such studies, 
and inhibitors working by various mechanisms could be used. Furthermore, the 
overexpression and/or knock down of specific HATs and HDACs might prove useful in 
exploring the molecular details underlying transcriptional activation by steroid hormone 
receptors. The comparison of factors recruited to the promoter in the presence of AR 
compared to GR, as well as the acetylation status of the promoter after treatment with 
HDAC inhibitors, may give clues to why these two receptors respond differently to these 
inhibitors. One approach to this could be to determine which HDACs are involved in AR- 
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versus GR-mediated transcription, possibly identifying factors that have unique roles in 
the two systems. It would also be of great interest to study the dynamics of AR on a 
natural promoter. In order to relate the ligand-dependent dynamics of AR to its role in 
prostate carcinogenesis, this should preferentially be evaluated in a prostate cancer cell 
line. This can be achieved by the recombinant incorporation of a serially amplified AR-
responsive promoter (e.g. the PSA promoter) into the chromosome of a prostate cancer 
cell line. Such a system would give further information about the physiological relevance 
of the highly dynamic interaction between AR and chromatin. A detailed understanding 
of how AR interacts with response elements of target genes will give significant insight 
into the regulation of AR-mediated transcription, an important aspect of normal 
physiology as well as in the development and progression of prostate cancer. 
63
REFERENCES
Abate-Shen, C. & Shen, M.M. (2002). Mouse models of prostate carcinogenesis. Trends Genet, 18, S1-5. 
Agoulnik, I.U. & Weigel, N.L. (2006). Androgen receptor action in hormone-dependent and recurrent 
prostate cancer. J Cell Biochem, 99, 362-72. 
Agresti, A., Scaffidi, P., Riva, A., Caiolfa, V.R. & Bianchi, M.E. (2005). GR and HMGB1 interact only 
within chromatin and influence each other's residence time. Mol Cell, 18, 109-21. 
Anderson, J. (2003). The role of antiandrogen monotherapy in the treatment of prostate cancer. BJU Int, 91,
455-61. 
Angelucci, A., Valentini, A., Millimaggi, D., Gravina, G.L., Miano, R., Dolo, V., Vicentini, C., Bologna, 
M., Federici, G. & Bernardini, S. (2006). Valproic acid induces apoptosis in prostate carcinoma cell 
lines by activation of multiple death pathways. Anticancer Drugs, 17, 1141-50. 
Archer, T.K., Lee, H.L., Cordingley, M.G., Mymryk, J.S., Fragoso, G., Berard, D.S. & Hager, G.L. (1994). 
Differential steroid hormone induction of transcription from the mouse mammary tumor virus 
promoter. Mol Endocrinol, 8, 568-76. 
Asirvatham, A.J., Schmidt, M., Gao, B. & Chaudhary, J. (2006). Androgens regulate the 
immune/inflammatory response and cell survival pathways in rat ventral prostate epithelial cells. 
Endocrinology, 147, 257-71. 
Bai, S., He, B. & Wilson, E.M. (2005). Melanoma antigen gene protein MAGE-11 regulates androgen 
receptor function by modulating the interdomain interaction. Mol Cell Biol, 25, 1238-57. 
Balk, S.P. (2002). Androgen receptor as a target in androgen-independent prostate cancer. Urology, 60,
132-8; discussion 138-9. 
Ban, Y., Wang, M.C., Watt, K.W., Loor, R. & Chu, T.M. (1984). The proteolytic activity of human 
prostate-specific antigen. Biochem Biophys Res Commun, 123, 482-8. 
Barak, M., Mecz, Y., Lurie, A. & Gruener, N. (1989). Evaluation of prostate-specific antigen as a marker 
for adenocarcinoma of the prostate. J Lab Clin Med, 113, 598-603. 
Beato, M. & Klug, J. (2000). Steroid hormone receptors: an update. Hum Reprod Update, 6, 225-36. 
Beaufort, N., Debela, M., Creutzburg, S., Kellermann, J., Bode, W., Schmitt, M., Pidard, D. & Magdolen, 
V. (2006). Interplay of human tissue kallikrein 4 (hK4) with the plasminogen activation system: hK4 
regulates the structure and functions of the urokinase-type plasminogen activator receptor (uPAR). 
Biol Chem, 387, 217-22. 
Becker, M., Baumann, C., John, S., Walker, D.A., Vigneron, M., McNally, J.G. & Hager, G.L. (2002). 
Dynamic behavior of transcription factors on a natural promoter in living cells. EMBO Rep, 3, 1188-
94. 
Belandia, B. & Parker, M.G. (2003). Nuclear receptors: a rendezvous for chromatin remodeling factors. 
Cell, 114, 277-80. 
Berger, S.L. (2002). Histone modifications in transcriptional regulation. Curr Opin Genet Dev, 12, 142-8. 
Bethel, C.R., Faith, D., Li, X., Guan, B., Hicks, J.L., Lan, F., Jenkins, R.B., Bieberich, C.J. & De Marzo, 
A.M. (2006). Decreased NKX3.1 protein expression in focal prostatic atrophy, prostatic intraepithelial 
neoplasia, and adenocarcinoma: association with gleason score and chromosome 8p deletion. Cancer 
Res, 66, 10683-90. 
Bhatia-Gaur, R., Donjacour, A.A., Sciavolino, P.J., Kim, M., Desai, N., Young, P., Norton, C.R., Gridley, 
T., Cardiff, R.D., Cunha, G.R., Abate-Shen, C. & Shen, M.M. (1999). Roles for Nkx3.1 in prostate 
development and cancer. Genes Dev, 13, 966-77. 
Bohl CE, G.W., Miller DD, Bell CE, Dalton JT. (2005). Structural basis for antagonism and resistance of 
bicalutamide in prostate cancer. Proc Natl Acad Sci U S A, 102, 6201-6. 
Borgono, C.A. & Diamandis, E.P. (2004). The emerging roles of human tissue kallikreins in cancer. Nat 
Rev Cancer, 4, 876-90. 
                          REFERENCES
64
Bosisio, D., Marazzi, I., Agresti, A., Shimizu, N., Bianchi, M.E. & Natoli, G. (2006). A hyper-dynamic 
equilibrium between promoter-bound and nucleoplasmic dimers controls NF-kappaB-dependent gene 
activity. Embo J, 25, 798-810. 
Bowen, C., Bubendorf, L., Voeller, H.J., Slack, R., Willi, N., Sauter, G., Gasser, T.C., Koivisto, P., Lack, 
E.E., Kononen, J., Kallioniemi, O.P. & Gelmann, E.P. (2000). Loss of NKX3.1 expression in human 
prostate cancers correlates with tumor progression. Cancer Res, 60, 6111-5. 
Burakov, D., Crofts, L.A., Chang, C.P. & Freedman, L.P. (2002). Reciprocal recruitment of DRIP/mediator 
and p160 coactivator complexes in vivo by estrogen receptor. J Biol Chem, 277, 14359-62. 
Burd, C.J., Morey, L.M. & Knudsen, K.E. (2006). Androgen receptor corepressors and prostate cancer. 
Endocr Relat Cancer, 13, 979-94. 
Butler, L.M., Agus, D.B., Scher, H.I., Higgins, B., Rose, A., Cordon-Cardo, C., Thaler, H.T., Rifkind, 
R.A., Marks, P.A. & Richon, V.M. (2000). Suberoylanilide hydroxamic acid, an inhibitor of histone 
deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res, 60, 5165-
70. 
Butler, L.M., Webb, Y., Agus, D.B., Higgins, B., Tolentino, T.R., Kutko, M.C., LaQuaglia, M.P., 
Drobnjak, M., Cordon-Cardo, C., Scher, H.I., Breslow, R., Richon, V.M., Rifkind, R.A. & Marks, P.A. 
(2001). Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, 
an inhibitor of histone deacetylase. Clin Cancer Res, 7, 962-70. 
Camacho, L.H., Olson, J., Tong, W.P., Young, C.W., Spriggs, D.R. & Malkin, M.G. (2007). Phase I dose 
escalation clinical trial of phenylbutyrate sodium administered twice daily to patients with advanced 
solid tumors. Invest New Drugs, 25, 131-8. 
Catley, L., Weisberg, E., Tai, Y.T., Atadja, P., Remiszewski, S., Hideshima, T., Mitsiades, N., 
Shringarpure, R., LeBlanc, R., Chauhan, D., Munshi, N.C., Schlossman, R., Richardson, P., Griffin, J. 
& Anderson, K.C. (2003). NVP-LAQ824 is a potent novel histone deacetylase inhibitor with 
significant activity against multiple myeloma. Blood, 102, 2615-22. 
Chamberlain, N.L., Driver, E.D. & Miesfeld, R.L. (1994). The length and location of CAG trinucleotide 
repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res,
22, 3181-6. 
Chen, C.D., Welsbie, D.S., Tran, C., Baek, S.H., Chen, R., Vessella, R., Rosenfeld, M.G. & Sawyers, C.L. 
(2004). Molecular determinants of resistance to antiandrogen therapy. Nat Med, 10, 33-9. 
Chen, S., Xu, Y., Yuan, X., Bubley, G.J. & Balk, S.P. (2006). Androgen receptor phosphorylation and 
stabilization in prostate cancer by cyclin-dependent kinase 1. Proc Natl Acad Sci U S A.
Chen, Z.X. & Breitman, T.R. (1994). Tributyrin: a prodrug of butyric acid for potential clinical application 
in differentiation therapy. Cancer Res, 54, 3494-9. 
Chung, L.W., Baseman, A., Assikis, V. & Zhau, H.E. (2005). Molecular insights into prostate cancer 
progression: the missing link of tumor microenvironment. J Urol, 173, 10-20. 
Clements, J., Hooper, J., Dong, Y. & Harvey, T. (2001). The expanded human kallikrein (KLK) gene 
family: genomic organisation, tissue-specific expression and potential functions. Biol Chem, 382, 5-14. 
Clements, J.A., Willemsen, N.M., Myers, S.A. & Dong, Y. (2004). The tissue kallikrein family of serine 
proteases: functional roles in human disease and potential as clinical biomarkers. Crit Rev Clin Lab 
Sci, 41, 265-312. 
Cloutier, S.M., Kundig, C., Felber, L.M., Fattah, O.M., Chagas, J.R., Gygi, C.M., Jichlinski, P., Leisinger, 
H.J. & Deperthes, D. (2004). Development of recombinant inhibitors specific to human kallikrein 2 
using phage-display selected substrates. Eur J Biochem, 271, 607-13. 
Conley, B.A., Egorin, M.J., Tait, N., Rosen, D.M., Sausville, E.A., Dover, G., Fram, R.J. & Van Echo, 
D.A. (1998). Phase I study of the orally administered butyrate prodrug, tributyrin, in patients with solid 
tumors. Clin Cancer Res, 4, 629-34. 
Constantinou, J. & Feneley, M.R. (2006). PSA testing: an evolving relationship with prostate cancer 
screening. Prostate Cancer Prostatic Dis, 9, 6-13. 
Culig, Z., Comuzzi, B., Steiner, H., Bartsch, G. & Hobisch, A. (2004). Expression and function of 
androgen receptor coactivators in prostate cancer. J Steroid Biochem Mol Biol, 92, 265-71. 
                          REFERENCES
65
Daher, R. & Beaini, M. (1998). Prostate-specific antigen and new related markers for prostate cancer. Clin 
Chem Lab Med, 36, 671-81. 
Day, C.H., Fanger, G.R., Retter, M.W., Hylander, B.L., Penetrante, R.B., Houghton, R.L., Zhang, X., 
McNeill, P.D., Filho, A.M., Nolasco, M., Badaro, R., Cheever, M.A., Reed, S.G., Dillon, D.C. & 
Watanabe, Y. (2002). Characterization of KLK4 expression and detection of KLK4-specific antibody 
in prostate cancer patient sera. Oncogene, 21, 7114-20. 
Dehm, S.M. & Tindall, D.J. (2006). Molecular regulation of androgen action in prostate cancer. J Cell 
Biochem, 99, 333-44. 
Denis, L.J. & Griffiths, K. (2000). Endocrine treatment in prostate cancer. Semin Surg Oncol, 18, 52-74. 
DePrimo, S.E., Diehn, M., Nelson, J.B., Reiter, R.E., Matese, J., Fero, M., Tibshirani, R., Brown, P.O. & 
Brooks, J.D. (2002). Transcriptional programs activated by exposure of human prostate cancer cells to 
androgen. Genome Biol, 3, RESEARCH0032. 
Di Cristofano, A. & Pandolfi, P.P. (2000). The multiple roles of PTEN in tumor suppression. Cell, 100,
387-90. 
Di Cristofano, A., Pesce, B., Cordon-Cardo, C. & Pandolfi, P.P. (1998). Pten is essential for embryonic 
development and tumour suppression. Nat Genet, 19, 348-55. 
Diamandis, E.P. & Yousef, G.M. (2002). Human tissue kallikreins: a family of new cancer biomarkers. 
Clin Chem, 48, 1198-205. 
Dilworth, F.J. & Chambon, P. (2001). Nuclear receptors coordinate the activities of chromatin remodeling 
complexes and coactivators to facilitate initiation of transcription. Oncogene, 20, 3047-54. 
Doesburg, P., Kuil, C.W., Berrevoets, C.A., Steketee, K., Faber, P.W., Mulder, E., Brinkmann, A.O. & 
Trapman, J. (1997). Functional in vivo interaction between the amino-terminal, transactivation domain 
and the ligand binding domain of the androgen receptor. Biochemistry, 36, 1052-64. 
Dong, Y., Bui, L.T., Odorico, D.M., Tan, O.L., Myers, S.A., Samaratunga, H., Gardiner, R.A. & Clements, 
J.A. (2005). Compartmentalized expression of kallikrein 4 (KLK4/hK4) isoforms in prostate cancer: 
nuclear, cytoplasmic and secreted forms. Endocr Relat Cancer, 12, 875-89. 
Drago, J.R., Badalament, R.A., Wientjes, M.G., Smith, J.J., Nesbitt, J.A., York, J.P., Ashton, J.J. & Neff, 
J.C. (1989). Relative value of prostate-specific antigen and prostatic acid phosphatase in diagnosis and 
management of adenocarcinoma of prostate. Ohio State University experience Urology, 34, 187-92. 
Dundr, M., Hoffmann-Rohrer, U., Hu, Q., Grummt, I., Rothblum, L.I., Phair, R.D. & Misteli, T. (2002). A 
kinetic framework for a mammalian RNA polymerase in vivo. Science, 298, 1623-6. 
Duvic, M., Talpur, R., Ni, X., Zhang, C., Hazarika, P., Kelly, C., Chiao, J.H., Reilly, J.F., Ricker, J.L., 
Richon, V.M. & Frankel, S.R. (2007). Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic 
acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood, 109, 31-9. 
Dyer, E.S., Paulsen, M.T., Markwart, S.M., Goh, M., Livant, D.L. & Ljungman, M. (2002). Phenylbutyrate 
inhibits the invasive properties of prostate and breast cancer cell lines in the sea urchin embryo 
basement membrane invasion assay. Int J Cancer, 101, 496-9. 
Elbi, C., Walker, D.A., Romero, G., Sullivan, W.P., Toft, D.O., Hager, G.L. & DeFranco, D.B. (2004). 
Molecular chaperones function as steroid receptor nuclear mobility factors. Proc Natl Acad Sci U S A,
101, 2876-81. 
Escriva, H., Delaunay, F. & Laudet, V. (2000). Ligand binding and nuclear receptor evolution. Bioessays,
22, 717-27. 
Evans, B.A., Drinkwater, C.C. & Richards, R.I. (1987). Mouse glandular kallikrein genes. Structure and 
partial sequence analysis of the kallikrein gene locus. J Biol Chem, 262, 8027-34. 
Farla, P., Hersmus, R., Geverts, B., Mari, P.O., Nigg, A.L., Dubbink, H.J., Trapman, J. & Houtsmuller, 
A.B. (2004). The androgen receptor ligand-binding domain stabilizes DNA binding in living cells. J
Struct Biol, 147, 50-61. 
Farla, P., Hersmus, R., Trapman, J. & Houtsmuller, A.B. (2005). Antiandrogens prevent stable DNA-
binding of the androgen receptor. J Cell Sci, 118, 4187-98. 
Faus, H. & Haendler, B. (2006). Post-translational modifications of steroid receptors. Biomed 
Pharmacother, 60, 520-8. 
                          REFERENCES
66
Feldman, B.J. & Feldman, D. (2001). The development of androgen-independent prostate cancer. Nat Rev 
Cancer, 1, 34-45. 
Ferguson, M., Henry, P.A. & Currie, R.A. (2003). Histone deacetylase inhibition is associated with 
transcriptional repression of the Hmga2 gene. Nucleic Acids Res, 31, 3123-33. 
Fernandez, P.L., Hernandez, L., Farre, X., Campo, E. & Cardesa, A. (2002). Alterations of cell cycle-
regulatory genes in prostate cancer. Pathobiology, 70, 1-10. 
Feuer, E.J., Merrill, R.M. & Hankey, B.F. (1999). Cancer surveillance series: interpreting trends in prostate 
cancer--part II: Cause of death misclassification and the recent rise and fall in prostate cancer 
mortality. J Natl Cancer Inst, 91, 1025-32. 
Fischle, W., Wang, Y. & Allis, C.D. (2003). Histone and chromatin cross-talk. Curr Opin Cell Biol, 15,
172-83. 
Fletcher, T.M., Xiao, N., Mautino, G., Baumann, C.T., Wolford, R., Warren, B.S. & Hager, G.L. (2002). 
ATP-dependent mobilization of the glucocorticoid receptor during chromatin remodeling. Mol Cell 
Biol, 22, 3255-63. 
Fragoso, G., Pennie, W.D., John, S. & Hager, G.L. (1998). The position and length of the steroid-dependent 
hypersensitive region in the mouse mammary tumor virus long terminal repeat are invariant despite 
multiple nucleosome B frames. Mol Cell Biol, 18, 3633-44. 
Freedman, L.P. & Luisi, B.F. (1993). On the mechanism of DNA binding by nuclear hormone receptors: a 
structural and functional perspective. J Cell Biochem, 51, 140-50. 
Freeman, E.R., Bloom, D.A. & McGuire, E.J. (2001). A brief history of testosterone. J Urol, 165, 371-3. 
Fronsdal, K., Engedal, N., Slagsvold, T. & Saatcioglu, F. (1998). CREB binding protein is a coactivator for 
the androgen receptor and mediates cross-talk with AP-1. J Biol Chem, 273, 31853-9. 
Fryer, C.J. & Archer, T.K. (1998). Chromatin remodelling by the glucocorticoid receptor requires the 
BRG1 complex. Nature, 393, 88-91. 
Fu, M., Rao, M., Wu, K., Wang, C., Zhang, X., Hessien, M., Yeung, Y.G., Gioeli, D., Weber, M.J. & 
Pestell, R.G. (2004). The androgen receptor acetylation site regulates cAMP and AKT but not ERK-
induced activity. J Biol Chem, 279, 29436-49. 
Fu, M., Wang, C., Reutens, A.T., Wang, J., Angeletti, R.H., Siconolfi-Baez, L., Ogryzko, V., Avantaggiati, 
M.L. & Pestell, R.G. (2000). p300 and p300/cAMP-response element-binding protein-associated factor 
acetylate the androgen receptor at sites governing hormone-dependent transactivation. J Biol Chem,
275, 20853-60. 
Fu, M., Wang, C., Wang, J., Zhang, X., Sakamaki, T., Yeung, Y.G., Chang, C., Hopp, T., Fuqua, S.A., 
Jaffray, E., Hay, R.T., Palvimo, J.J., Janne, O.A. & Pestell, R.G. (2002). Androgen receptor acetylation 
governs trans activation and MEKK1-induced apoptosis without affecting in vitro sumoylation and 
trans-repression function. Mol Cell Biol, 22, 3373-88. 
Fujimoto, N., Yeh, S., Kang, H.Y., Inui, S., Chang, H.C., Mizokami, A. & Chang, C. (1999). Cloning and 
characterization of androgen receptor coactivator, ARA55, in human prostate. J Biol Chem, 274, 8316-
21. 
Furumai, R., Matsuyama, A., Kobashi, N., Lee, K.H., Nishiyama, M., Nakajima, H., Tanaka, A., Komatsu, 
Y., Nishino, N., Yoshida, M. & Horinouchi, S. (2002). FK228 (depsipeptide) as a natural prodrug that 
inhibits class I histone deacetylases. Cancer Res, 62, 4916-21. 
Gallinari, P., Marco, S.D., Jones, P., Pallaoro, M. & Steinkuhler, C. (2007). HDACs, histone deacetylation 
and gene transcription: from molecular biology to cancer therapeutics. Cell Res.
Gan, L., Lee, I., Smith, R., Argonza-Barrett, R., Lei, H., McCuaig, J., Moss, P., Paeper, B. & Wang, K. 
(2000). Sequencing and expression analysis of the serine protease gene cluster located in chromosome 
19q13 region. Gene, 257, 119-30. 
Gao, J., Collard, R.L., Bui, L., Herington, A.C., Nicol, D.L. & Clements, J.A. (2007). Kallikrein 4 is a 
potential mediator of cellular interactions between cancer cells and osteoblasts in metastatic prostate 
cancer. Prostate, 67, 348-360. 
Geserick, C., Meyer, H.A. & Haendler, B. (2005). The role of DNA response elements as allosteric 
modulators of steroid receptor function. Mol Cell Endocrinol, 236, 1-7. 
                          REFERENCES
67
Gingrich, J.R., Barrios, R.J., Kattan, M.W., Nahm, H.S., Finegold, M.J. & Greenberg, N.M. (1997). 
Androgen-independent prostate cancer progression in the TRAMP model. Cancer Res, 57, 4687-91. 
Gioeli, D., Black, B.E., Gordon, V., Spencer, A., Kesler, C.T., Eblen, S.T., Paschal, B.M. & Weber, M.J. 
(2006). Stress kinase signaling regulates androgen receptor phosphorylation, transcription, and 
localization. Mol Endocrinol, 20, 503-15. 
Gioeli, D., Ficarro, S.B., Kwiek, J.J., Aaronson, D., Hancock, M., Catling, A.D., White, F.M., Christian, 
R.E., Settlage, R.E., Shabanowitz, J., Hunt, D.F. & Weber, M.J. (2002). Androgen receptor 
phosphorylation. Regulation and identification of the phosphorylation sites. J Biol Chem, 277, 29304-
14. 
Giovannucci, E., Stampfer, M.J., Krithivas, K., Brown, M., Dahl, D., Brufsky, A., Talcott, J., Hennekens, 
C.H. & Kantoff, P.W. (1997). The CAG repeat within the androgen receptor gene and its relationship 
to prostate cancer. Proc Natl Acad Sci U S A, 94, 3320-3. 
Gojo, I., Jiemjit, A., Trepel, J.B., Sparreboom, A., Figg, W.D., Rollins, S., Tidwell, M.L., Greer, J., Chung, 
E.J., Lee, M.J., Gore, S.D., Sausville, E.A., Zwiebel, J. & Karp, J.E. (2006). Phase 1 and 
pharmacological study of MS-275, a histone deacetylase inhibitor, in adults with refractory and 
relapsed acute leukemias. Blood.
Gore, S.D., Weng, L.J., Figg, W.D., Zhai, S., Donehower, R.C., Dover, G., Grever, M.R., Griffin, C., 
Grochow, L.B., Hawkins, A., Burks, K., Zabelena, Y. & Miller, C.B. (2002). Impact of prolonged 
infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes 
and acute myeloid leukemia. Clin Cancer Res, 8, 963-70. 
Gottlicher, M., Minucci, S., Zhu, P., Kramer, O.H., Schimpf, A., Giavara, S., Sleeman, J.P., Lo Coco, F., 
Nervi, C., Pelicci, P.G. & Heinzel, T. (2001). Valproic acid defines a novel class of HDAC inhibitors 
inducing differentiation of transformed cells. Embo J, 20, 6969-78. 
Greenberg, N.M., DeMayo, F., Finegold, M.J., Medina, D., Tilley, W.D., Aspinall, J.O., Cunha, G.R., 
Donjacour, A.A., Matusik, R.J. & Rosen, J.M. (1995). Prostate cancer in a transgenic mouse. Proc 
Natl Acad Sci U S A, 92, 3439-43. 
Gregory, R.I. & Shiekhattar, R. (2004). Chromatin modifiers and carcinogenesis. Trends Cell Biol, 14, 695-
702. 
Greschik H, M.D. (2003). Structure-activity relationship of nuclear receptor-ligand interactions. Curr Top 
Med Chem., 3, 1573-99. 
Guo, Z., Dai, B., Jiang, T., Xu, K., Xie, Y., Kim, O., Nesheiwat, I., Kong, X., Melamed, J., Handratta, 
V.D., Njar, V.C., Brodie, A.M., Yu, L.R., Veenstra, T.D., Chen, H. & Qiu, Y. (2006). Regulation of 
androgen receptor activity by tyrosine phosphorylation. Cancer Cell, 10, 309-19. 
Haese, A., Vaisanen, V., Lilja, H., Kattan, M.W., Rittenhouse, H.G., Pettersson, K., Chan, D.W., Huland, 
H., Sokoll, L.J. & Partin, A.W. (2005). Comparison of predictive accuracy for pathologically organ 
confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific 
antigen combined with clinical stage and Gleason grade. J Urol, 173, 752-6. 
Hager, G.L. (2001). Understanding nuclear receptor function: from DNA to chromatin to the interphase 
nucleus. Prog Nucleic Acid Res Mol Biol, 66, 279-305. 
Hager, G.L., Elbi, C., Johnson, T.A., Voss, T., Nagaich, A.K., Schiltz, R.L., Qiu, Y. & John, S. (2006). 
Chromatin dynamics and the evolution of alternate promoter states. Chromosome Res, 14, 107-16. 
Hager, G.L., Nagaich, A.K., Johnson, T.A., Walker, D.A. & John, S. (2004). Dynamics of nuclear receptor 
movement and transcription. Biochim Biophys Acta, 1677, 46-51. 
Hardy, D.O., Scher, H.I., Bogenreider, T., Sabbatini, P., Zhang, Z.F., Nanus, D.M. & Catterall, J.F. (1996). 
Androgen receptor CAG repeat lengths in prostate cancer: correlation with age of onset. J Clin 
Endocrinol Metab, 81, 4400-5. 
Hart, P.S., Hart, T. C. (2006). Mutation in kallikrein 4 cause autosomal recessive hypomaturation 
amelogenesis imperfecta. J Med Genet.
He, B., Gampe, R.T., Jr., Kole, A.J., Hnat, A.T., Stanley, T.B., An, G., Stewart, E.L., Kalman, R.I., 
Minges, J.T. & Wilson, E.M. (2004). Structural basis for androgen receptor interdomain and 
                          REFERENCES
68
coactivator interactions suggests a transition in nuclear receptor activation function dominance. Mol 
Cell, 16, 425-38. 
He, B., Kemppainen, J.A. & Wilson, E.M. (2000). FXXLF and WXXLF sequences mediate the NH2-
terminal interaction with the ligand binding domain of the androgen receptor. J Biol Chem, 275,
22986-94. 
He, W.W., Sciavolino, P.J., Wing, J., Augustus, M., Hudson, P., Meissner, P.S., Curtis, R.T., Shell, B.K., 
Bostwick, D.G., Tindall, D.J., Gelmann, E.P., Abate-Shen, C. & Carter, K.C. (1997). A novel human 
prostate-specific, androgen-regulated homeobox gene (NKX3.1) that maps to 8p21, a region frequently 
deleted in prostate cancer. Genomics, 43, 69-77. 
Heinlein, C.A. & Chang, C. (2002). Androgen receptor (AR) coregulators: an overview. Endocr Rev, 23,
175-200. 
Horoszewicz, J.S., Leong, S.S., Chu, T.M., Wajsman, Z.L., Friedman, M., Papsidero, L., Kim, U., Chai, 
L.S., Kakati, S., Arya, S.K. & Sandberg, A.A. (1980). The LNCaP cell line-a new model for studies on 
human prostatic carcinoma. Prog Clin Biol Res, 37, 115-32. 
Hsiao, P.W., Fryer, C.J., Trotter, K.W., Wang, W. & Archer, T.K. (2003). BAF60a mediates critical 
interactions between nuclear receptors and the BRG1 chromatin-remodeling complex for 
transactivation. Mol Cell Biol, 23, 6210-20. 
Hsu, C.L., Chen, Y.L., Ting, H.J., Lin, W.J., Yang, Z., Zhang, Y., Wang, L., Wu, C.T., Chang, H.C., Yeh, 
S., Pimplikar, S.W. & Chang, C. (2005). Androgen receptor (AR) NH2- and COOH-terminal 
interactions result in the differential influences on the AR-mediated transactivation and cell growth. 
Mol Endocrinol, 19, 350-61. 
Hu, J.C., Sun, X., Zhang, C., Liu, S., Bartlett, J.D. & Simmer, J.P. (2002). Enamelysin and kallikrein-4 
mRNA expression in developing mouse molars. Eur J Oral Sci, 110, 307-15. 
Huang, Z.Q., Li, J., Sachs, L.M., Cole, P.A. & Wong, J. (2003). A role for cofactor-cofactor and cofactor-
histone interactions in targeting p300, SWI/SNF and Mediator for transcription. Embo J, 22, 2146-55. 
Huggins, C., Hodges, CV. (1941). Studies on prostatic cancer:effect of castration, of estrogen and of 
androgen injection on serum phosthatases in metastatic carcinoma of the prostate. Cancer Res, 1, 293-
7. 
Ikonen, T., Palvimo, J.J. & Janne, O.A. (1997). Interaction between the amino- and carboxyl-terminal 
regions of the rat androgen receptor modulates transcriptional activity and is influenced by nuclear 
receptor coactivators. J Biol Chem, 272, 29821-8. 
Irvine, R.A., Yu, M.C., Ross, R.K. & Coetzee, G.A. (1995). The CAG and GGC microsatellites of the 
androgen receptor gene are in linkage disequilibrium in men with prostate cancer. Cancer Res, 55,
1937-40. 
Isaacs, J.T. (1994). Role of androgens in prostatic cancer. Vitam Horm, 49, 433-502. 
Isaacs, J.T. & Coffey, D.S. (1989). Etiology and disease process of benign prostatic hyperplasia. Prostate 
Suppl, 2, 33-50. 
Jankevicius, F., Miller, S.M. & Ackermann, R. (2002). Nutrition and risk of prostate cancer. Urol Int, 68,
69-80. 
Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J. & Thun, M.J. (2007). Cancer statistics, 2007. CA Cancer 
J Clin, 57, 43-66. 
Jenster, G., Trapman, J. & Brinkmann, A.O. (1993). Nuclear import of the human androgen receptor. 
Biochem J, 293 ( Pt 3), 761-8. 
Jenster, G., van der Korput, H.A., Trapman, J. & Brinkmann, A.O. (1995). Identification of two 
transcription activation units in the N-terminal domain of the human androgen receptor. J Biol Chem,
270, 7341-6. 
Jenster, G., van der Korput, H.A., van Vroonhoven, C., van der Kwast, T.H., Trapman, J. & Brinkmann, 
A.O. (1991). Domains of the human androgen receptor involved in steroid binding, transcriptional 
activation, and subcellular localization. Mol Endocrinol, 5, 1396-404. 
Jenuwein, T. & Allis, C.D. (2001). Translating the histone code. Science, 293, 1074-80. 
                          REFERENCES
69
Kadam, S. & Emerson, B.M. (2003). Transcriptional specificity of human SWI/SNF BRG1 and BRM 
chromatin remodeling complexes. Mol Cell, 11, 377-89. 
Kaighn, M.E., Narayan, K.S., Ohnuki, Y., Lechner, J.F. & Jones, L.W. (1979). Establishment and 
characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol, 17, 16-23. 
Kang, Z., Janne, O.A. & Palvimo, J.J. (2004). Coregulator recruitment and histone modifications in 
transcriptional regulation by the androgen receptor. Mol Endocrinol, 18, 2633-48. 
Kantoff, P., Giovannucci, E. & Brown, M. (1998). The androgen receptor CAG repeat polymorphism and 
its relationship to prostate cancer. Biochim Biophys Acta, 1378, C1-5. 
Karayi, M.K. & Markham, A.F. (2004). Molecular biology of prostate cancer. Prostate Cancer Prostatic 
Dis, 7, 6-20. 
Kato, Y., Salumbides, B.C., Wang, X.F., Qian, D.Z., Williams, S., Wei, Y., Sanni, T.B., Atadja, P. & Pili, 
R. (2007). Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-
retinoic acid in human malignant melanoma. Mol Cancer Ther, 6, 70-81. 
Kazemi-Esfarjani, P., Trifiro, M.A. & Pinsky, L. (1995). Evidence for a repressive function of the long 
polyglutamine tract in the human androgen receptor: possible pathogenetic relevance for the (CAG)n-
expanded neuronopathies. Hum Mol Genet, 4, 523-7. 
Kemppainen JA, L.M., Sar M, Wilson EM. (1992). Androgen receptor phosphorylation, turnover, nuclear 
transport, and transcriptional activation. Specificity for steroids and antihormones. J Biol Chem., 267,
968-74. 
Khorasanizadeh, S. & Rastinejad, F. (2001). Nuclear-receptor interactions on DNA-response elements. 
Trends Biochem Sci, 26, 384-90. 
Kijima, M., Yoshida, M., Sugita, K., Horinouchi, S. & Beppu, T. (1993). Trapoxin, an antitumor cyclic 
tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase. J Biol Chem, 268, 22429-
35. 
Kim, M.J., Cardiff, R.D., Desai, N., Banach-Petrosky, W.A., Parsons, R., Shen, M.M. & Abate-Shen, C. 
(2002). Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis. 
Proc Natl Acad Sci U S A, 99, 2884-9. 
Klein, K.A., Reiter, R.E., Redula, J., Moradi, H., Zhu, X.L., Brothman, A.R., Lamb, D.J., Marcelli, M., 
Belldegrun, A., Witte, O.N. & Sawyers, C.L. (1997). Progression of metastatic human prostate cancer 
to androgen independence in immunodeficient SCID mice. Nat Med, 3, 402-8. 
Klotz, L. (2000). Hormone therapy for patients with prostate carcinoma. Cancer, 88, 3009-14. 
Korkmaz, C.G., Fronsdal, K., Zhang, Y., Lorenzo, P.I. & Saatcioglu, F. (2004a). Potentiation of androgen 
receptor transcriptional activity by inhibition of histone deacetylation--rescue of transcriptionally 
compromised mutants. J Endocrinol, 182, 377-89. 
Korkmaz, C.G., Korkmaz, K.S., Manola, J., Xi, Z., Risberg, B., Danielsen, H., Kung, J., Sellers, W.R., 
Loda, M. & Saatcioglu, F. (2004b). Analysis of androgen regulated homeobox gene NKX3.1 during 
prostate carcinogenesis. J Urol, 172, 1134-9. 
Korkmaz, K.S., Korkmaz, C.G., Pretlow, T.G. & Saatcioglu, F. (2001). Distinctly different gene structure 
of KLK4/KLK-L1/prostase/ARM1 compared with other members of the kallikrein family: intracellular 
localization, alternative cDNA forms, and Regulation by multiple hormones. DNA Cell Biol, 20, 435-
45. 
Kramer, P.R., Fragoso, G., Pennie, W., Htun, H., Hager, G.L. & Sinden, R.R. (1999). Transcriptional state 
of the mouse mammary tumor virus promoter can affect topological domain size in vivo. J Biol Chem,
274, 28590-7. 
Kraus, W.L., McInerney, E.M. & Katzenellenbogen, B.S. (1995). Ligand-dependent, transcriptionally 
productive association of the amino- and carboxyl-terminal regions of a steroid hormone nuclear 
receptor. Proc Natl Acad Sci U S A, 92, 12314-8. 
Krithivas, K., Yurgalevitch, S.M., Mohr, B.A., Wilcox, C.J., Batter, S.J., Brown, M., Longcope, C., 
McKinlay, J.B. & Kantoff, P.W. (1999). Evidence that the CAG repeat in the androgen receptor gene 
is associated with the age-related decline in serum androgen levels in men. J Endocrinol, 162, 137-42. 
                          REFERENCES
70
Kuendgen, A., Knipp, S., Fox, F., Strupp, C., Hildebrandt, B., Steidl, C., Germing, U., Haas, R. & 
Gattermann, N. (2005). Results of a phase 2 study of valproic acid alone or in combination with all-
trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute 
myeloid leukemia. Ann Hematol, 84 Suppl 13, 61-6. 
Kuo, M.H. & Allis, C.D. (1998). Roles of histone acetyltransferases and deacetylases in gene regulation. 
Bioessays, 20, 615-26. 
Kurlender, L., Borgono, C., Michael, I.P., Obiezu, C., Elliott, M.B., Yousef, G.M. & Diamandis, E.P. 
(2005). A survey of alternative transcripts of human tissue kallikrein genes. Biochim Biophys Acta,
1755, 1-14. 
La Spada, A.R., Wilson, E.M., Lubahn, D.B., Harding, A.E. & Fischbeck, K.H. (1991). Androgen receptor 
gene mutations in X-linked spinal and bulbar muscular atrophy. Nature, 352, 77-9. 
Lallemand, F., Courilleau, D., Sabbah, M., Redeuilh, G. & Mester, J. (1996). Direct inhibition of the 
expression of cyclin D1 gene by sodium butyrate. Biochem Biophys Res Commun, 229, 163-9. 
Langley, E., Kemppainen, J.A. & Wilson, E.M. (1998). Intermolecular NH2-/carboxyl-terminal 
interactions in androgen receptor dimerization revealed by mutations that cause androgen insensitivity. 
J Biol Chem, 273, 92-101. 
Langley, E., Zhou, Z.X. & Wilson, E.M. (1995). Evidence for an anti-parallel orientation of the ligand-
activated human androgen receptor dimer. J Biol Chem, 270, 29983-90. 
Laribee, R.N. & Klemsz, M.J. (2001). Loss of PU.1 expression following inhibition of histone 
deacetylases. J Immunol, 167, 5160-6. 
Lee, B.I., Park, S.H., Kim, J.W., Sausville, E.A., Kim, H.T., Nakanishi, O., Trepel, J.B. & Kim, S.J. (2001). 
MS-275, a histone deacetylase inhibitor, selectively induces transforming growth factor beta type II 
receptor expression in human breast cancer cells. Cancer Res, 61, 931-4. 
Lemon, B. & Tjian, R. (2000). Orchestrated response: a symphony of transcription factors for gene control. 
Genes Dev, 14, 2551-69. 
Levy, M.A., Brandt, M., Heys, J.R., Holt, D.A. & Metcalf, B.W. (1990). Inhibition of rat liver steroid 5 
alpha-reductase by 3-androstene-3-carboxylic acids: mechanism of enzyme-inhibitor interaction. 
Biochemistry, 29, 2815-24. 
Li, J., Fu, J., Toumazou, C., Yoon, H.G. & Wong, J. (2006). A role of the amino-terminal (N) and 
carboxyl-terminal (C) interaction in binding of androgen receptor to chromatin. Mol Endocrinol, 20,
776-85. 
Liao, L., Kuang, S.Q., Yuan, Y., Gonzalez, S.M., O'Malley, B.W. & Xu, J. (2002). Molecular structure and 
biological function of the cancer-amplified nuclear receptor coactivator SRC-3/AIB1. J Steroid 
Biochem Mol Biol, 83, 3-14. 
Lilja, H. (1985). A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle 
protein. J Clin Invest, 76, 1899-903. 
Lilja, H. (2003). Biology of prostate-specific antigen. Urology, 62, 27-33. 
Lilja, H., Abrahamsson, P.A. & Lundwall, A. (1989). Semenogelin, the predominant protein in human 
semen. Primary structure and identification of closely related proteins in the male accessory sex glands 
and on the spermatozoa. J Biol Chem, 264, 1894-900. 
Lin, H.K., Wang, L., Hu, Y.C., Altuwaijri, S. & Chang, C. (2002). Phosphorylation-dependent 
ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase. Embo J, 21,
4037-48. 
List, H.J., Lozano, C., Lu, J., Danielsen, M., Wellstein, A. & Riegel, A.T. (1999a). Comparison of 
chromatin remodeling and transcriptional activation of the mouse mammary tumor virus promoter by 
the androgen and glucocorticoid receptor. Exp Cell Res, 250, 414-22. 
List, H.J., Smith, C.L., Rodriguez, O., Danielsen, M. & Riegel, A.T. (1999b). Inhibition of histone 
deacetylation augments dihydrotestosterone induction of androgen receptor levels: an explanation for 
trichostatin A effects on androgen-induced chromatin remodeling and transcription of the mouse 
mammary tumor virus promoter. Exp Cell Res, 252, 471-8. 
                          REFERENCES
71
Loprevite, M., Tiseo, M., Grossi, F., Scolaro, T., Semino, C., Pandolfi, A., Favoni, R. & Ardizzoni, A. 
(2005). In vitro study of CI-994, a histone deacetylase inhibitor, in non-small cell lung cancer cell 
lines. Oncol Res, 15, 39-48. 
LoRusso, P.M., Demchik, L., Foster, B., Knight, J., Bissery, M.C., Polin, L.M., Leopold, W.R., 3rd & 
Corbett, T.H. (1996). Preclinical antitumor activity of CI-994. Invest New Drugs, 14, 349-56. 
Lubahn, D.B., Joseph, D.R., Sar, M., Tan, J., Higgs, H.N., Larson, R.E., French, F.S. & Wilson, E.M. 
(1988a). The human androgen receptor: complementary deoxyribonucleic acid cloning, sequence 
analysis and gene expression in prostate. Mol Endocrinol, 2, 1265-75. 
Lubahn, D.B., Joseph, D.R., Sullivan, P.M., Willard, H.F., French, F.S. & Wilson, E.M. (1988b). Cloning 
of human androgen receptor complementary DNA and localization to the X chromosome. Science,
240, 327-30. 
Mangelsdorf, D.J., Thummel, C., Beato, M., Herrlich, P., Schutz, G., Umesono, K., Blumberg, B., Kastner, 
P., Mark, M., Chambon, P. & Evans, R.M. (1995). The nuclear receptor superfamily: the second 
decade. Cell, 83, 835-9. 
Marcelli, M., Stenoien, D.L., Szafran, A.T., Simeoni, S., Agoulnik, I.U., Weigel, N.L., Moran, T., Mikic, I., 
Price, J.H. & Mancini, M.A. (2006). Quantifying effects of ligands on androgen receptor nuclear 
translocation, intranuclear dynamics, and solubility. J Cell Biochem, 98, 770-88. 
Marks, P.A., Miller, T. & Richon, V.M. (2003). Histone deacetylases. Curr Opin Pharmacol, 3, 344-51. 
Marshall, T.W., Link, K.A., Petre-Draviam, C.E. & Knudsen, K.E. (2003). Differential requirement of 
SWI/SNF for androgen receptor activity. J Biol Chem, 278, 30605-13. 
Marshall, W.F., Straight, A., Marko, J.F., Swedlow, J., Dernburg, A., Belmont, A., Murray, A.W., Agard, 
D.A. & Sedat, J.W. (1997). Interphase chromosomes undergo constrained diffusional motion in living 
cells. Curr Biol, 7, 930-9. 
Masiello, D., Cheng, S., Bubley, G.J., Lu, M.L. & Balk, S.P. (2002). Bicalutamide functions as an 
androgen receptor antagonist by assembly of a transcriptionally inactive receptor. J Biol Chem, 277,
26321-6. 
Matias, P.M., Donner, P., Coelho, R., Thomaz, M., Peixoto, C., Macedo, S., Otto, N., Joschko, S., Scholz, 
P., Wegg, A., Basler, S., Schafer, M., Egner, U. & Carrondo, M.A. (2000). Structural evidence for 
ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic 
gene mutations. J Biol Chem, 275, 26164-71. 
McKenna, N.J. & O'Malley, B.W. (2002). Combinatorial control of gene expression by nuclear receptors 
and coregulators. Cell, 108, 465-74. 
McNally, J.G., Muller, W.G., Walker, D., Wolford, R. & Hager, G.L. (2000). The glucocorticoid receptor: 
rapid exchange with regulatory sites in living cells. Science, 287, 1262-5. 
Melchior, S.W., Brown, L.G., Figg, W.D., Quinn, J.E., Santucci, R.A., Brunner, J., Thuroff, J.W., Lange, 
P.H. & Vessella, R.L. (1999). Effects of phenylbutyrate on proliferation and apoptosis in human 
prostate cancer cells in vitro and in vivo. Int J Oncol, 14, 501-8. 
Metivier, R., Penot, G., Hubner, M.R., Reid, G., Brand, H., Kos, M. & Gannon, F. (2003). Estrogen 
receptor-alpha directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target 
promoter. Cell, 115, 751-63. 
Metivier, R., Reid, G. & Gannon, F. (2006). Transcription in four dimensions: nuclear receptor-directed 
initiation of gene expression. EMBO Rep, 7, 161-7. 
Misteli, T. (2001). Protein dynamics: implications for nuclear architecture and gene expression. Science,
291, 843-7. 
Miyamoto, H., Messing, E.M. & Chang, C. (2004). Androgen deprivation therapy for prostate cancer: 
current status and future prospects. Prostate, 61, 332-53. 
Miyamoto, H., Yeh, S., Wilding, G. & Chang, C. (1998). Promotion of agonist activity of antiandrogens by 
the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells. Proc Natl Acad Sci 
U S A, 95, 7379-84. 
Monneret, C. (2005). Histone deacetylase inhibitors. Eur J Med Chem, 40, 1-13. 
                          REFERENCES
72
Mymryk, J.S. & Archer, T.K. (1995). Dissection of progesterone receptor-mediated chromatin remodeling 
and transcriptional activation in vivo. Genes Dev, 9, 1366-76. 
Nagaich, A.K., Rayasam, G.V., Martinez, E.D., Becker, M., Qiu, Y., Johnson, T.A., Elbi, C., Fletcher, 
T.M., John, S. & Hager, G.L. (2004a). Subnuclear trafficking and gene targeting by steroid receptors. 
Ann N Y Acad Sci, 1024, 213-20. 
Nagaich, A.K., Walker, D.A., Wolford, R. & Hager, G.L. (2004b). Rapid periodic binding and 
displacement of the glucocorticoid receptor during chromatin remodeling. Mol Cell, 14, 163-74. 
Nagano, T., Oida, S., Ando, H., Gomi, K., Arai, T. & Fukae, M. (2003). Relative levels of mRNA encoding 
enamel proteins in enamel organ epithelia and odontoblasts. J Dent Res, 82, 982-6. 
Nantermet, P.V., Masarachia, P., Gentile, M.A., Pennypacker, B., Xu, J., Holder, D., Gerhold, D., Towler, 
D., Schmidt, A., Kimmel, D.B., Freedman, L.P., Harada, S. & Ray, W.J. (2005). Androgenic induction 
of growth and differentiation in the rodent uterus involves the modulation of estrogen-regulated 
genetic pathways. Endocrinology, 146, 564-78. 
Narlikar, G.J., Fan, H.Y. & Kingston, R.E. (2002). Cooperation between complexes that regulate chromatin 
structure and transcription. Cell, 108, 475-87. 
Navarro, D., Luzardo, O.P., Fernandez, L., Chesa, N. & Diaz-Chico, B.N. (2002). Transition to androgen-
independence in prostate cancer. J Steroid Biochem Mol Biol, 81, 191-201. 
Nelson, P.S., Clegg, N., Arnold, H., Ferguson, C., Bonham, M., White, J., Hood, L. & Lin, B. (2002). The 
program of androgen-responsive genes in neoplastic prostate epithelium. Proc Natl Acad Sci U S A, 99,
11890-5. 
Nelson, P.S., Gan, L., Ferguson, C., Moss, P., Gelinas, R., Hood, L. & Wang, K. (1999). Molecular cloning 
and characterization of prostase, an androgen-regulated serine protease with prostate-restricted 
expression. Proc Natl Acad Sci U S A, 96, 3114-9. 
Newmark, H.L., Lupton, J.R. & Young, C.W. (1994). Butyrate as a differentiating agent: pharmacokinetics, 
analogues and current status. Cancer Lett, 78, 1-5. 
Nye, A.C., Rajendran, R.R., Stenoien, D.L., Mancini, M.A., Katzenellenbogen, B.S. & Belmont, A.S. 
(2002). Alteration of large-scale chromatin structure by estrogen receptor. Mol Cell Biol, 22, 3437-49. 
Obiezu, C.V., Shan, S.J., Soosaipillai, A., Luo, L.Y., Grass, L., Sotiropoulou, G., Petraki, C.D., 
Papanastasiou, P.A., Levesque, M.A. & Diamandis, E.P. (2005). Human kallikrein 4: quantitative 
study in tissues and evidence for its secretion into biological fluids. Clin Chem, 51, 1432-42. 
Obiezu, C.V., Soosaipillai, A., Jung, K., Stephan, C., Scorilas, A., Howarth, D.H. & Diamandis, E.P. 
(2002). Detection of human kallikrein 4 in healthy and cancerous prostatic tissues by 
immunofluorometry and immunohistochemistry. Clin Chem, 48, 1232-40. 
Olsson, A.Y. & Lundwall, A. (2002). Organization and evolution of the glandular kallikrein locus in Mus 
musculus. Biochem Biophys Res Commun, 299, 305-11. 
Ornstein, D.K., Cinquanta, M., Weiler, S., Duray, P.H., Emmert-Buck, M.R., Vocke, C.D., Linehan, W.M. 
& Ferretti, J.A. (2001). Expression studies and mutational analysis of the androgen regulated 
homeobox gene NKX3.1 in benign and malignant prostate epithelium. J Urol, 165, 1329-34. 
Orphanides, G. & Reinberg, D. (2002). A unified theory of gene expression. Cell, 108, 439-51. 
Paliouras, M., Borgono, C. & Diamandis, E.P. (2007). Human tissue kallikreins: The cancer biomarker 
family. Cancer Lett, 249, 61-79. 
Parkin, D.M., Bray, F.I. & Devesa, S.S. (2001). Cancer burden in the year 2000. The global picture. Eur J 
Cancer, 37 Suppl 8, S4-66. 
Partin, A.W., Hanks, G.E., Klein, E.A., Moul, J.W., Nelson, W.G. & Scher, H.I. (2002). Prostate-specific 
antigen as a marker of disease activity in prostate cancer. Oncology (Williston Park), 16, 1218-24; 
discussion 1224, 1227-8 passim. 
Peehl, D.M. (2005). Primary cell cultures as models of prostate cancer development. Endocr Relat Cancer,
12, 19-47. 
Pereira de Jesus-Tran, K., Cote, P.L., Cantin, L., Blanchet, J., Labrie, F. & Breton, R. (2006). Comparison 
of crystal structures of human androgen receptor ligand-binding domain complexed with various 
agonists reveals molecular determinants responsible for binding affinity. Protein Sci, 15, 987-99. 
                          REFERENCES
73
Peterson, C.L. (2002). Chromatin remodeling enzymes: taming the machines. Third in review series on 
chromatin dynamics. EMBO Rep, 3, 319-22. 
Peterson, C.L., Dingwall, A. & Scott, M.P. (1994). Five SWI/SNF gene products are components of a large 
multisubunit complex required for transcriptional enhancement. Proc Natl Acad Sci U S A, 91, 2905-8. 
Phair, R.D. & Misteli, T. (2000). High mobility of proteins in the mammalian cell nucleus. Nature, 404,
604-9. 
Phair, R.D., Scaffidi, P., Elbi, C., Vecerova, J., Dey, A., Ozato, K., Brown, D.T., Hager, G., Bustin, M. & 
Misteli, T. (2004). Global nature of dynamic protein-chromatin interactions in vivo: three-dimensional 
genome scanning and dynamic interaction networks of chromatin proteins. Mol Cell Biol, 24, 6393-
402. 
Piekarz, R.L., Frye, A.R., Wright, J.J., Steinberg, S.M., Liewehr, D.J., Rosing, D.R., Sachdev, V., Fojo, T. 
& Bates, S.E. (2006). Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial 
for T-cell lymphoma. Clin Cancer Res, 12, 3762-73. 
Pirtskhalaishvili, G., Hrebinko, R.L. & Nelson, J.B. (2001). The treatment of prostate cancer: an overview 
of current options. Cancer Pract, 9, 295-306. 
Plumb, J.A., Finn, P.W., Williams, R.J., Bandara, M.J., Romero, M.R., Watkins, C.J., La Thangue, N.B. & 
Brown, R. (2003). Pharmacodynamic response and inhibition of growth of human tumor xenografts by 
the novel histone deacetylase inhibitor PXD101. Mol Cancer Ther, 2, 721-8. 
Poujol, N., Wurtz, J.M., Tahiri, B., Lumbroso, S., Nicolas, J.C., Moras, D. & Sultan, C. (2000). Specific 
recognition of androgens by their nuclear receptor. A structure-function study. J Biol Chem, 275,
24022-31. 
Poukka, H., Karvonen, U., Janne, O.A. & Palvimo, J.J. (2000). Covalent modification of the androgen 
receptor by small ubiquitin-like modifier 1 (SUMO-1). Proc Natl Acad Sci U S A, 97, 14145-50. 
Powell, I.J. (2007). Epidemiology and pathophysiology of prostate cancer in African-American men. J
Urol, 177, 444-9. 
Prasad, K.N. (1980). Butyric acid: a small fatty acid with diverse biological functions. Life Sci, 27, 1351-8. 
Pratt, W.B., Gehring, U. & Toft, D.O. (1996). Molecular chaperoning of steroid hormone receptors. Exs,
77, 79-95. 
Puente, X.S., Sanchez, L.M., Overall, C.M. & Lopez-Otin, C. (2003). Human and mouse proteases: a 
comparative genomic approach. Nat Rev Genet, 4, 544-58. 
Qian, X., LaRochelle, W.J., Ara, G., Wu, F., Petersen, K.D., Thougaard, A., Sehested, M., Lichenstein, 
H.S. & Jeffers, M. (2006). Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian 
cancer studies. Mol Cancer Ther, 5, 2086-95. 
Qiu, Y., Zhao, Y., Becker, M., John, S., Parekh, B.S., Huang, S., Hendarwanto, A., Martinez, E.D., Chen, 
Y., Lu, H., Adkins, N.L., Stavreva, D.A., Wiench, M., Georgel, P.T., Schiltz, R.L. & Hager, G.L. 
(2006). HDAC1 acetylation is linked to progressive modulation of steroid receptor-induced gene 
transcription. Mol Cell, 22, 669-79. 
Quinn, M. & Babb, P. (2002a). Patterns and trends in prostate cancer incidence, survival, prevalence and 
mortality. Part I: international comparisons. BJU Int, 90, 162-73. 
Quinn, M. & Babb, P. (2002b). Patterns and trends in prostate cancer incidence, survival, prevalence and 
mortality. Part II: individual countries. BJU Int, 90, 174-84. 
Rashid, S.F., Moore, J.S., Walker, E., Driver, P.M., Engel, J., Edwards, C.E., Brown, G., Uskokovic, M.R. 
& Campbell, M.J. (2001). Synergistic growth inhibition of prostate cancer cells by 1 alpha,25 
Dihydroxyvitamin D(3) and its 19-nor-hexafluoride analogs in combination with either sodium 
butyrate or trichostatin A. Oncogene, 20, 1860-72. 
Rawlings, N.D. & Barrett, A.J. (1993). Evolutionary families of peptidases. Biochem J, 290 ( Pt 1), 205-18. 
Rayasam, G.V., Elbi, C., Walker, D.A., Wolford, R., Fletcher, T.M., Edwards, D.P. & Hager, G.L. (2005). 
Ligand-Specific Dynamics of the Progesterone Receptor in Living Cells and during Chromatin 
Remodeling In Vitro. Mol Cell Biol, 25, 2406-18. 
                          REFERENCES
74
Reid, G., Hubner, M.R., Metivier, R., Brand, H., Denger, S., Manu, D., Beaudouin, J., Ellenberg, J. & 
Gannon, F. (2003). Cyclic, proteasome-mediated turnover of unliganded and liganded ERalpha on 
responsive promoters is an integral feature of estrogen signaling. Mol Cell, 11, 695-707. 
Reid, T., Valone, F., Lipera, W., Irwin, D., Paroly, W., Natale, R., Sreedharan, S., Keer, H., Lum, B., 
Scappaticci, F. & Bhatnagar, A. (2004). Phase II trial of the histone deacetylase inhibitor 
pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer. Lung Cancer, 45,
381-6. 
Riegman, P.H., Vlietstra, R.J., Suurmeijer, L., Cleutjens, C.B. & Trapman, J. (1992). Characterization of 
the human kallikrein locus. Genomics, 14, 6-11. 
Rigaud, G., Roux, J., Pictet, R. & Grange, T. (1991). In vivo footprinting of rat TAT gene: dynamic 
interplay between the glucocorticoid receptor and a liver-specific factor. Cell, 67, 977-86. 
Rittenhouse, H.G., Finlay, J.A., Mikolajczyk, S.D. & Partin, A.W. (1998). Human Kallikrein 2 (hK2) and 
prostate-specific antigen (PSA): two closely related, but distinct, kallikreins in the prostate. Crit Rev 
Clin Lab Sci, 35, 275-368. 
Robins, D.M., Scheller, A. & Adler, A.J. (1994). Specific steroid response from a nonspecific DNA 
element. J Steroid Biochem Mol Biol, 49, 251-5. 
Robinson-Rechavi, M., Escriva Garcia, H. & Laudet, V. (2003). The nuclear receptor superfamily. J Cell 
Sci, 116, 585-6. 
Rosner, W., Hryb, D.J., Khan, M.S., Nakhla, A.M. & Romas, N.A. (1999). Sex hormone-binding globulin 
mediates steroid hormone signal transduction at the plasma membrane. J Steroid Biochem Mol Biol,
69, 481-5. 
Ruefli, A.A., Ausserlechner, M.J., Bernhard, D., Sutton, V.R., Tainton, K.M., Kofler, R., Smyth, M.J. & 
Johnstone, R.W. (2001). The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide 
hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and 
production of reactive oxygen species. Proc Natl Acad Sci U S A, 98, 10833-8. 
Sack, J.S., Kish, K.F., Wang, C., Attar, R.M., Kiefer, S.E., An, Y., Wu, G.Y., Scheffler, J.E., Salvati, M.E., 
Krystek, S.R., Jr., Weinmann, R. & Einspahr, H.M. (2001). Crystallographic structures of the ligand-
binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist 
dihydrotestosterone. Proc Natl Acad Sci U S A, 98, 4904-9. 
Salma, N., Xiao, H., Mueller, E. & Imbalzano, A.N. (2004). Temporal recruitment of transcription factors 
and SWI/SNF chromatin-remodeling enzymes during adipogenic induction of the peroxisome 
proliferator-activated receptor gamma nuclear hormone receptor. Mol Cell Biol, 24, 4651-63. 
Sasakawa, Y., Naoe, Y., Inoue, T., Sasakawa, T., Matsuo, M., Manda, T. & Mutoh, S. (2003a). Effects of 
FK228, a novel histone deacetylase inhibitor, on tumor growth and expression of p21 and c-myc genes 
in vivo. Cancer Lett, 195, 161-8. 
Sasakawa, Y., Naoe, Y., Noto, T., Inoue, T., Sasakawa, T., Matsuo, M., Manda, T. & Mutoh, S. (2003b). 
Antitumor efficacy of FK228, a novel histone deacetylase inhibitor, depends on the effect on 
expression of angiogenesis factors. Biochem Pharmacol, 66, 897-906. 
Schaffner, W. (1988). Gene regulation. A hit-and-run mechanism for transcriptional activation? Nature,
336, 427-8. 
Schaufele, F., Carbonell, X., Guerbadot, M., Borngraeber, S., Chapman, M.S., Ma, A.A., Miner, J.N. & 
Diamond, M.I. (2005). The structural basis of androgen receptor activation: intramolecular and 
intermolecular amino-carboxy interactions. Proc Natl Acad Sci U S A, 102, 9802-7. 
Seeler, J.S. & Dejean, A. (2003). Nuclear and unclear functions of SUMO. Nat Rev Mol Cell Biol, 4, 690-9. 
Shang, Y., Hu, X., DiRenzo, J., Lazar, M.A. & Brown, M. (2000). Cofactor dynamics and sufficiency in 
estrogen receptor-regulated transcription. Cell, 103, 843-52. 
Shang, Y., Myers, M. & Brown, M. (2002). Formation of the androgen receptor transcription complex. Mol
Cell, 9, 601-10. 
Shenk, J.L., Fisher, C.J., Chen, S.Y., Zhou, X.F., Tillman, K. & Shemshedini, L. (2001). p53 represses 
androgen-induced transactivation of prostate-specific antigen by disrupting hAR amino- to carboxyl-
terminal interaction. J Biol Chem, 276, 38472-9. 
                          REFERENCES
75
Siavoshian, S., Segain, J.P., Kornprobst, M., Bonnet, C., Cherbut, C., Galmiche, J.P. & Blottiere, H.M. 
(2000). Butyrate and trichostatin A effects on the proliferation/differentiation of human intestinal 
epithelial cells: induction of cyclin D3 and p21 expression. Gut, 46, 507-14. 
Simental, J.A., Sar, M., Lane, M.V., French, F.S. & Wilson, E.M. (1991). Transcriptional activation and 
nuclear targeting signals of the human androgen receptor. J Biol Chem, 266, 510-8. 
Simmer, J.P. & Hu, J.C. (2002). Expression, structure, and function of enamel proteinases. Connect Tissue 
Res, 43, 441-9. 
Singh, R.R. & Kumar, R. (2005). Steroid hormone receptor signaling in tumorigenesis. J Cell Biochem, 96,
490-505. 
Sissons, G.R., Clements, R., Peeling, W.B. & Penney, M.D. (1992). Can serum prostate-specific antigen 
replace bone scintigraphy in the follow-up of metastatic prostatic cancer? Br J Radiol, 65, 861-4. 
Slagsvold, T., Kraus, I., Bentzen, T., Palvimo, J. & Saatcioglu, F. (2000). Mutational analysis of the 
androgen receptor AF-2 (activation function 2) core domain reveals functional and mechanistic 
differences of conserved residues compared with other nuclear receptors. Mol Endocrinol, 14, 1603-
17. 
Smith, C.L., Htun, H., Wolford, R.G. & Hager, G.L. (1997). Differential activity of progesterone and 
glucocorticoid receptors on mouse mammary tumor virus templates differing in chromatin structure. J
Biol Chem, 272, 14227-35. 
So, A.I., Hurtado-Coll, A. & Gleave, M.E. (2003). Androgens and prostate cancer. World J Urol, 21, 325-
37. 
Southard-Smith, M., Pierce, J.C. & MacDonald, R.J. (1994). Physical mapping of the rat tissue kallikrein 
family in two gene clusters by analysis of P1 bacteriophage clones. Genomics, 22, 404-17. 
Stamey, T.A., Yang, N., Hay, A.R., McNeal, J.E., Freiha, F.S. & Redwine, E. (1987). Prostate-specific 
antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med, 317, 909-16. 
Stavreva, D.A., Muller, W.G., Hager, G.L., Smith, C.L. & McNally, J.G. (2004). Rapid glucocorticoid 
receptor exchange at a promoter is coupled to transcription and regulated by chaperones and 
proteasomes. Mol Cell Biol, 24, 2682-97. 
Steketee, K., Berrevoets, C.A., Dubbink, H.J., Doesburg, P., Hersmus, R., Brinkmann, A.O. & Trapman, J. 
(2002). Amino acids 3-13 and amino acids in and flanking the 23FxxLF27 motif modulate the 
interaction between the N-terminal and ligand-binding domain of the androgen receptor. Eur J 
Biochem, 269, 5780-91. 
Stenman, U.H. (1999). New ultrasensitive assays facilitate studies on the role of human glandular kallikrein 
(hK2) as a marker for prostatic disease. Clin Chem, 45, 753-4. 
Stenoien, D.L., Nye, A.C., Mancini, M.G., Patel, K., Dutertre, M., O'Malley, B.W., Smith, C.L., Belmont, 
A.S. & Mancini, M.A. (2001a). Ligand-mediated assembly and real-time cellular dynamics of estrogen 
receptor alpha-coactivator complexes in living cells. Mol Cell Biol, 21, 4404-12. 
Stenoien, D.L., Patel, K., Mancini, M.G., Dutertre, M., Smith, C.L., O'Malley, B.W. & Mancini, M.A. 
(2001b). FRAP reveals that mobility of oestrogen receptor-alpha is ligand- and proteasome-dependent. 
Nat Cell Biol, 3, 15-23. 
Stephan, C., Jung, K., Diamandis, E.P., Rittenhouse, H.G., Lein, M. & Loening, S.A. (2002). Prostate-
specific antigen, its molecular forms, and other kallikrein markers for detection of prostate cancer 
Urology, 59, 2-8. 
Stephan, C., Jung, K., Soosaipillai, A., Yousef, G.M., Cammann, H., Meyer, H., Xu, C. & Diamandis, E.P. 
(2005). Clinical utility of human glandular kallikrein 2 within a neural network for prostate cancer 
detection. BJU Int, 96, 521-7. 
Stephanopoulos, G., Garefalaki, M.E. & Lyroudia, K. (2005). Genes and related proteins involved in 
amelogenesis imperfecta. J Dent Res, 84, 1117-26. 
Stephenson, S.A., Verity, K., Ashworth, L.K. & Clements, J.A. (1999). Localization of a new prostate-
specific antigen-related serine protease gene, KLK4, is evidence for an expanded human kallikrein 
gene family cluster on chromosome 19q13.3-13.4. J Biol Chem, 274, 23210-4. 
                          REFERENCES
76
Stone, K.R., Mickey, D.D., Wunderli, H., Mickey, G.H. & Paulson, D.F. (1978). Isolation of a human 
prostate carcinoma cell line (DU 145). Int J Cancer, 21, 274-81. 
Takayama, T.K., McMullen, B.A., Nelson, P.S., Matsumura, M. & Fujikawa, K. (2001). Characterization 
of hK4 (prostase), a prostate-specific serine protease: activation of the precursor of prostate specific 
antigen (pro-PSA) and single-chain urokinase-type plasminogen activator and degradation of prostatic 
acid phosphatase. Biochemistry, 40, 15341-8. 
Tan, J., Sharief, Y., Hamil, K.G., Gregory, C.W., Zang, D.Y., Sar, M., Gumerlock, P.H., deVere White, 
R.W., Pretlow, T.G., Harris, S.E., Wilson, E.M., Mohler, J.L. & French, F.S. (1997). 
Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent 
human prostate cancer xenograft CWR22 and LNCaP cells. Mol Endocrinol, 11, 450-9. 
Taylor, R.A., Cowin, P.A., Cunha, G.R., Pera, M., Trounson, A.O., Pedersen, J. & Risbridger, G.P. (2006). 
Formation of human prostate tissue from embryonic stem cells. Nat Methods, 3, 179-81. 
Thomas, M., Dadgar, N., Aphale, A., Harrell, J.M., Kunkel, R., Pratt, W.B. & Lieberman, A.P. (2004). 
Androgen receptor acetylation site mutations cause trafficking defects, misfolding, and aggregation 
similar to expanded glutamine tracts. J Biol Chem, 279, 8389-95. 
Tut, T.G., Ghadessy, F.J., Trifiro, M.A., Pinsky, L. & Yong, E.L. (1997). Long polyglutamine tracts in the 
androgen receptor are associated with reduced trans-activation, impaired sperm production, and male 
infertility. J Clin Endocrinol Metab, 82, 3777-82. 
van Bokhoven, A., Varella-Garcia, M., Korch, C., Johannes, W.U., Smith, E.E., Miller, H.L., Nordeen, 
S.K., Miller, G.J. & Lucia, M.S. (2003). Molecular characterization of human prostate carcinoma cell 
lines. Prostate, 57, 205-25. 
van Weerden, W.M. & Romijn, J.C. (2000). Use of nude mouse xenograft models in prostate cancer 
research. Prostate, 43, 263-71. 
Veldscholte, J., Berrevoets, C.A., Brinkmann, A.O., Grootegoed, J.A. & Mulder, E. (1992). Anti-androgens 
and the mutated androgen receptor of LNCaP cells: differential effects on binding affinity, heat-shock 
protein interaction, and transcription activation. Biochemistry, 31, 2393-9. 
Veldscholte, J., Ris-Stalpers, C., Kuiper, G.G., Jenster, G., Berrevoets, C., Claassen, E., van Rooij, H.C., 
Trapman, J., Brinkmann, A.O. & Mulder, E. (1990). A mutation in the ligand binding domain of the 
androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-
androgens. Biochem Biophys Res Commun, 173, 534-40. 
Verdone, L., Caserta, M. & Di Mauro, E. (2005). Role of histone acetylation in the control of gene 
expression. Biochem Cell Biol, 83, 344-53. 
Veveris-Lowe, T.L., Lawrence, M.G., Collard, R.L., Bui, L., Herington, A.C., Nicol, D.L. & Clements, 
J.A. (2005). Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-
cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cells. Endocr
Relat Cancer, 12, 631-43. 
Vrana, J.A., Decker, R.H., Johnson, C.R., Wang, Z., Jarvis, W.D., Richon, V.M., Ehinger, M., Fisher, P.B. 
& Grant, S. (1999). Induction of apoptosis in U937 human leukemia cells by suberoylanilide 
hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and 
p21CIP1, but independent of p53. Oncogene, 18, 7016-25. 
Wallberg, A.E., Neely, K.E., Hassan, A.H., Gustafsson, J.A., Workman, J.L. & Wright, A.P. (2000). 
Recruitment of the SWI-SNF chromatin remodeling complex as a mechanism of gene activation by the 
glucocorticoid receptor tau1 activation domain. Mol Cell Biol, 20, 2004-13. 
Wang, L., Hsu, C.L. & Chang, C. (2005a). Androgen receptor corepressors: an overview. Prostate, 63,
117-30. 
Wang, Q., Carroll, J.S. & Brown, M. (2005b). Spatial and temporal recruitment of androgen receptor and 
its coactivators involves chromosomal looping and polymerase tracking. Mol Cell, 19, 631-42. 
Wang, R., Xu, J., Juliette, L., Castilleja, A., Love, J., Sung, S.Y., Zhau, H.E., Goodwin, T.J. & Chung, 
L.W. (2005c). Three-dimensional co-culture models to study prostate cancer growth, progression, and 
metastasis to bone. Semin Cancer Biol, 15, 353-64. 
                          REFERENCES
77
Wen, Y., Hu, M.C., Makino, K., Spohn, B., Bartholomeusz, G., Yan, D.H. & Hung, M.C. (2000). HER-
2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt 
pathway. Cancer Res, 60, 6841-5. 
Wiseman, H. & Duffy, R. (2001). New advances in the understanding of the role of steroids and steroid 
receptors in disease. Biochem Soc Trans, 29, 205-9. 
Xia, Q., Sung, J., Chowdhury, W., Chen, C.L., Hoti, N., Shabbeer, S., Carducci, M. & Rodriguez, R. 
(2006). Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in 
vivo. Cancer Res, 66, 7237-44. 
Xu, L.L., Srikantan, V., Sesterhenn, I.A., Augustus, M., Dean, R., Moul, J.W., Carter, K.C. & Srivastava, 
S. (2000). Expression profile of an androgen regulated prostate specific homeobox gene NKX3.1 in 
primary prostate cancer. J Urol, 163, 972-9. 
Yamamoto, K.R. (1985). Steroid receptor regulated transcription of specific genes and gene networks. 
Annu Rev Genet, 19, 209-52. 
Yoshida, M., Horinouchi, S. & Beppu, T. (1995). Trichostatin A and trapoxin: novel chemical probes for 
the role of histone acetylation in chromatin structure and function. Bioessays, 17, 423-30. 
Yoshida, M., Nomura, S. & Beppu, T. (1987). Effects of trichostatins on differentiation of murine 
erythroleukemia cells. Cancer Res, 47, 3688-91. 
Yousef, G.M. & Diamandis, E.P. (2002). Human tissue kallikreins: a new enzymatic cascade pathway? 
Biol Chem, 383, 1045-57. 
Yousef, G.M., Kopolovic, A.D., Elliott, M.B. & Diamandis, E.P. (2003). Genomic overview of serine 
proteases. Biochem Biophys Res Commun, 305, 28-36. 
Yousef, G.M., Obiezu, C.V., Luo, L.Y., Black, M.H. & Diamandis, E.P. (1999). Prostase/KLK-L1 is a new 
member of the human kallikrein gene family, is expressed in prostate and breast tissues, and is 
hormonally regulated. Cancer Res, 59, 4252-6. 
Zhou, Z., Corden, J.L. & Brown, T.R. (1997). Identification and characterization of a novel androgen 
response element composed of a direct repeat. J Biol Chem, 272, 8227-35. 
Zhou, Z.X., Sar, M., Simental, J.A., Lane, M.V. & Wilson, E.M. (1994). A ligand-dependent bipartite 
nuclear targeting signal in the human androgen receptor. Requirement for the DNA-binding domain 
and modulation by NH2-terminal and carboxyl-terminal sequences. J Biol Chem, 269, 13115-23. 
Zhu, P., Baek, S.H., Bourk, E.M., Ohgi, K.A., Garcia-Bassets, I., Sanjo, H., Akira, S., Kotol, P.F., Glass, 
C.K., Rosenfeld, M.G. & Rose, D.W. (2006). Macrophage/cancer cell interactions mediate hormone 
resistance by a nuclear receptor derepression pathway. Cell, 124, 615-29. 
Zimra, Y., Wasserman, L., Maron, L., Shaklai, M., Nudelman, A. & Rephaeli, A. (1997). Butyric acid and 
pivaloyloxymethyl butyrate, AN-9, a novel butyric acid derivative, induce apoptosis in HL-60 cells. J
Cancer Res Clin Oncol, 123, 152-60. 
